
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2005

Or

Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934

FOR THE TRANSITION PERIOD FROM TO

Commission File Number: 001-32283

QUADRAMED CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

DELAWARE
(State or Other Jurisdiction of
Incorporation or Organization)

52-1992861
(IRS Employer
Identification No.)

12110 SUNSET HILLS ROAD, SUITE 600,
RESTON, VIRGINIA
(Address of Principal Executive Offices)

20190
(Zip Code)

(703) 709-2300
(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act.) Yes No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes No

As of September 30, 2005, there were 40,683,388 shares of the Registrant's common stock outstanding, par value \$0.01.

QUADRAMED CORPORATION
REPORT ON FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2005
TABLE OF CONTENTS

	<u>Page</u>
PART I. FINANCIAL INFORMATION	
Item 1. Financial Statements	
Condensed Consolidated Balance Sheets (unaudited) as of September 30, 2005 and December 31, 2004	3
Condensed Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2005 and 2004	4
Condensed Consolidated Statements of Changes in Stockholders' Equity and Comprehensive Loss (unaudited) for the nine months ended September 30, 2005	5
Condensed Consolidated Statements of Cash Flows (unaudited) for the three and nine months ended September 30, 2005 and 2004	6
Notes to Condensed Consolidated Financial Statements	7
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3. Quantitative and Qualitative Disclosures About Market Risk	42
Item 4. Controls and Procedures	43
PART II. OTHER INFORMATION	
Item 1. Legal Proceedings	46
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	46
Item 4. Submission of Matters to a Vote of Security Holders	47
Item 6. Exhibits and Reports on Form 8-K	48
Signatures	49

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

QUADRAMED CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except per share amounts)
(unaudited)

	September 30, 2005	December 31, 2004
ASSETS		
Current assets		
Cash and cash equivalents	\$ 33,992	\$ 22,429
Accounts receivable, net of allowance for doubtful accounts of \$4,597 and \$3,303, respectively	26,062	25,550
Unbilled and other receivables	3,092	6,603
Notes and other receivables	563	832
Prepaid expenses and other current assets	9,425	8,001
Total current assets	73,134	63,415
Restricted cash	2,350	3,889
Property and equipment, net	4,122	5,129
Capitalized software development costs, net	698	1,427
Goodwill	25,983	25,983
Other intangible assets, net	8,413	12,451
Other long-term assets	4,631	7,116
Total assets	\$ 119,331	\$ 119,410
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities		
Accounts payable and accrued expenses	\$ 4,017	\$ 4,501
Accrued payroll and related	9,624	7,637
Other accrued liabilities	8,728	8,549
Dividends payable	10,311	13,780
Deferred revenue	50,025	44,040
Total current liabilities	82,705	78,507
Accrued exit cost of facility closing	4,021	2,898
Other long-term liabilities	2,482	5,366
Total liabilities	89,208	86,771
Stockholders' equity		
Preferred stock, \$0.01 par, 5,000 shares authorized, 4,000 shares issued and outstanding	87,008	83,412
Common stock, \$0.01 par, 150,000 shares authorized; 40,683 and 40,043 shares issued and outstanding, respectively	407	400
Additional paid-in-capital	302,044	301,231
Deferred compensation	—	(1,870)
Accumulated other comprehensive loss	(168)	(124)
Accumulated deficit	(359,168)	(350,410)
Total stockholders' equity	30,123	32,639
Total liabilities and stockholders' equity	\$ 119,331	\$ 119,410

The accompanying notes are an integral part of these condensed consolidated financial statements.

QUADRAMED CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)

	<u>Three months ended,</u> <u>September 30,</u>		<u>Nine months ended</u> <u>September 30,</u>	
	<u>2005</u>	<u>2004</u>	<u>2005</u>	<u>2004</u>
Revenue				
Services	\$ 2,824	\$ 2,924	\$ 9,448	\$ 8,947
Maintenance	13,767	12,839	41,152	36,149
Installation and other	3,196	3,276	8,300	9,837
Services and other revenue	19,787	19,039	58,900	54,933
Licenses	10,009	9,562	30,143	33,236
Hardware	250	2,175	2,061	7,723
Total revenue	<u>30,046</u>	<u>30,776</u>	<u>91,104</u>	<u>95,892</u>
Cost of revenue				
Cost of services and other revenue	7,326	7,670	21,764	22,976
Royalties and other	2,385	2,173	6,811	7,637
Amortization of acquired technology and capitalized software	1,014	791	3,073	2,142
Cost of license revenue	3,399	2,964	9,884	9,779
Cost of hardware revenue	682	1,829	2,190	5,435
Total cost of revenue	<u>11,407</u>	<u>12,463</u>	<u>33,838</u>	<u>38,190</u>
Gross margin	<u>18,639</u>	<u>18,313</u>	<u>57,266</u>	<u>57,702</u>
Operating expense				
General and administration	8,340	7,765	20,625	24,328
Software development	7,812	7,137	23,253	21,082
Sales and marketing	3,160	5,962	10,727	17,787
Amortization of intangible assets and depreciation	1,087	1,106	3,793	3,132
Loss on lease obligation	1,066	—	1,066	—
Total operating expenses	<u>21,465</u>	<u>21,970</u>	<u>59,464</u>	<u>66,329</u>
Loss from operations	<u>(2,826)</u>	<u>(3,657)</u>	<u>(2,198)</u>	<u>(8,627)</u>
Other income (expense)				
Interest expense, includes non-cash charges of \$383, \$235 and \$740, \$1,717	(403)	(283)	(763)	(4,662)
Interest income	223	107	444	351
Other income (expense), net	(21)	17	(37)	134
Loss on retirement of debt	—	(11,726)	—	(14,871)
Benefit (provision) for income taxes	(114)	(1)	(128)	161
Other income (expense)	<u>(315)</u>	<u>(11,886)</u>	<u>(484)</u>	<u>(18,887)</u>
Net loss from continuing operations	<u>\$ (3,141)</u>	<u>\$ (15,543)</u>	<u>\$ (2,682)</u>	<u>\$ (27,514)</u>
Loss from discontinued operations	(817)	(748)	(2,503)	(2,988)
Net loss	<u>\$ (3,958)</u>	<u>\$ (16,291)</u>	<u>\$ (5,185)</u>	<u>\$ (30,502)</u>
Preferred stock accretion	(1,207)	(1,348)	(3,573)	(1,348)
Net loss attributable to common shareholders	<u>\$ (5,165)</u>	<u>\$ (17,639)</u>	<u>\$ (8,758)</u>	<u>\$ (31,850)</u>
Income (loss) per share-basic and diluted				
Continuing operations	(0.11)	(0.42)	(0.15)	(0.83)
Discontinued operations	(0.02)	(0.02)	(0.07)	(0.09)
Net income (loss)	<u>\$ (0.13)</u>	<u>\$ (0.44)</u>	<u>\$ (0.22)</u>	<u>\$ (0.92)</u>
Weighted average shares outstanding				
Basic and diluted	<u>40,684</u>	<u>39,779</u>	<u>40,407</u>	<u>34,621</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

QUADRAMED CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF
CHANGES IN STOCKHOLDERS' EQUITY AND COMPREHENSIVE LOSS
(in thousands)
(unaudited)

	(Share #) Preferred Stock	Preferred Stock	(Share #) Common and Treasury Stock	Common and Treasury Stock	Additional Paid-in Capital	Deferred Compensation	Accumulated Other Comprehensive Income (loss) and Accumulated Deficit	Total Stockholder's Equity
Balance, December 31, 2004	4,000	\$83,412	40,043	\$400	\$301,231	\$(1,870)	\$(350,534)	\$32,639
Issuance of common stock	—	—	640	7	813	—	—	820
Accretion of preferred stock	—	3,573	—	—	—	—	—	3,573
Amortization of deferred compensation	—	—	—	—	—	1,870	—	1,870
Other	—	23	—	—	—	—	(44)	(21)
Net loss	—	—	—	—	—	—	(8,758)	(8,758)
Balance, September 30, 2005	<u>4,000</u>	<u>\$87,008</u>	<u>40,683</u>	<u>\$407</u>	<u>\$302,044</u>	<u>\$ —</u>	<u>\$(359,336)</u>	<u>\$30,123</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

QUADRAMED CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)

	<u>Three months ended</u> <u>September 30,</u>		<u>Nine months ended</u> <u>September 30,</u>	
	<u>2005</u>	<u>2004</u>	<u>2005</u>	<u>2004</u>
Cash flows from operating activities				
Net loss attributable to common shareholders	\$ (5,165)	\$(17,639)	\$ (8,758)	\$(31,850)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:				
Depreciation and amortization	3,465	2,398	9,478	8,044
Preferred stock accretion	1,207	—	3,573	—
Loss on retirement of debt	—	12,569	—	14,871
Exit cost of facility closing and other costs	1,066	—	1,066	—
Impairment and other charges for Financial Services Division	817	—	1,731	—
Gain on sale of assets	(383)	—	(383)	—
Provision for bad debts and other	879	1,923	1,704	3,015
Changes in assets and liabilities:				
Accounts receivable	4,447	620	(2,170)	4,728
Prepaid expenses and other	1,728	559	4,718	957
Accounts payable and accrued liabilities	310	2,395	(2,881)	(3,687)
Deferred revenue	(2,331)	(4,852)	6,065	(5,796)
Cash provided by (used in) operating activities	<u>6,040</u>	<u>(2,027)</u>	<u>14,143</u>	<u>(9,718)</u>
Cash flows from investing activities				
Proceeds from sale of assets and available-for-sale securities	446	38	345	114
Decrease in restricted cash	8	3	1,539	1,560
Acquisition of Détente	—	—	—	(4,074)
Acquisition of Tempus	—	(96)	—	(5,148)
Capital expenditures	(297)	(1,176)	(1,101)	(3,469)
Cash provided by (used in) investing activities	<u>157</u>	<u>(1,231)</u>	<u>783</u>	<u>(11,017)</u>
Cash flows from financing activities				
Proceeds from issuance of common stock and other	239	193	845	1,763
Proceeds from issuance of preferred stock, net of issuance cost	—	(11)	—	96,120
Payment of preferred stock dividends	(1,458)	—	(4,208)	—
Repayments under notes and subordinated debentures	—	(62,322)	—	(88,090)
Foreign currency translation effect on cash equivalents	—	30	—	30
Cash provided by (used in) financing activities	<u>(1,219)</u>	<u>(62,110)</u>	<u>(3,363)</u>	<u>9,823</u>
Net increase (decrease) in cash and cash equivalents	4,978	(65,368)	11,563	(10,912)
Cash and cash equivalents, beginning of period	<u>29,014</u>	<u>91,400</u>	<u>22,429</u>	<u>36,944</u>
Cash and cash equivalents, end of period	<u>\$33,992</u>	<u>\$ 26,032</u>	<u>\$33,992</u>	<u>\$ 26,032</u>
Supplemental disclosure of cash flow information				
Cash paid for interest	—	1,767	—	4,249
Net cash (refunded) paid for taxes	—	2	—	(161)
Supplemental disclosure of non cash flow information				
Issuance of common stock upon acquisition of Tempus	—	(1)	—	7,650

The accompanying notes are an integral part of these condensed consolidated financial statements.

QUADRAMED CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2005

NOTE 1. THE COMPANY

QuadraMed Corporation along with its subsidiaries, (the “Company” or “QuadraMed”) is dedicated to improving healthcare delivery by providing innovative healthcare information technology and services. QuadraMed provides healthcare information technology products and services that help healthcare providers to improve the quality of the care they deliver and the efficiency with which it is delivered. QuadraMed does this by developing and implementing sophisticated, user-friendly software applications designed and developed by the healthcare professionals and software specialists we employ.

Our products are designed to eliminate paper, improve processes, and decrease errors through the efficient management of patient clinical and financial records. They are suitable for acute care hospitals, specialty hospitals, Veterans Health Administration facilities and associated/affiliated businesses such as outpatient clinics, long-term care facilities, and rehabilitation hospitals and are used by healthcare organizations of varying size—from small single entity hospitals to large multi-facility care delivery organizations. Our products are sold as standalone, bundled, or fully integrated software packages. We have, in the past, provided services to support a hospital’s collection of receivables and its administration of contractual reimbursements from managed care companies; however, this segment of our business was discontinued in the first quarter of 2005.

Since 2004 we have been managed in two distinct segments, the Software Division and the Financial Services Division. In February 2004, we acquired Détente Systems Pty Limited of Sydney, Australia, a vendor of laboratory management software (“Détente”), and in June 2004 we acquired Tempus Software, Inc. of Jacksonville, Florida, a vendor of enterprise-wide hospital scheduling software (“Tempus”). The operations of both Tempus and Détente have been rolled into our Software Division. On December 15, 2004, QuadraMed announced the closing of the Financial Services Division; its operations ceased to exist in February 2005. Beginning 2005, the Company considers itself to be in a single reporting segment, specifically the software segment, as a result of the discontinued operations of the Financial Services Division in the first quarter of 2005. The financial results for these operating segments for prior periods have been reclassified to conform to the current period presentation.

NOTE 2. SIGNIFICANT ACCOUNTING POLICIES

Financial Statement Presentation

These condensed consolidated financial statements are unaudited and have been prepared in conformity with generally accepted accounting principles and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States for complete financial statements. It is suggested that these interim financial statements be read in conjunction with the consolidated financial statements, and the notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2004, as amended. In the opinion of management, the condensed consolidated financial statements for the periods presented herein include all normal and recurring adjustments that are necessary for a fair presentation of the results for these interim periods. The results of operations for the three and nine months ended September 30, 2005 are not necessarily indicative of the results for the entire year ending December 31, 2005.

Principles of Consolidation

These condensed consolidated financial statements include our accounts and all our significant business divisions and subsidiaries. Since February 2004, results of operations of Détente have been included in the

Company's condensed consolidated statements of operations, and the results of operations of Tempus have been included in the Company's consolidated statements of operations since July 2004. All significant intercompany accounts and transactions between the Company and our subsidiaries have been eliminated in the consolidated financial statements.

Use of Estimates in Preparation of Financial Statements

QuadraMed makes estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities, contingent assets and liabilities, revenues, and expenses. Significant estimates and assumptions have been made regarding revenue recognition, the allowance for doubtful accounts, contingencies, litigation, intangibles resulting from our purchase business combinations and other amounts. QuadraMed bases its estimates and assumptions on historical experience and on various other assumptions which management believes to be reasonable under the circumstances. Uncertainties inherent in these estimates include, among other things, significant estimates within percentage-of-completion accounting. In addition, QuadraMed annually reviews and tests its estimates related to the valuations of intangibles including acquired technology, goodwill, customer lists, trademarks and other intangibles, and capitalized software. Actual results may differ materially from these estimates.

Reclassifications

Certain reclassifications have been made to prior year balances to conform to the current year presentation.

Revenue Recognition

QuadraMed's revenue is principally generated from three sources: (i) licensing arrangements, (ii) services and (iii) hardware.

The Company's license revenue consists of fees for licenses of proprietary and third-party software. Cost of license revenue primarily includes the costs of third party software and royalties, and amortization of acquired technology and capitalized software. The Company's services revenue consists of maintenance, software installation, customer training and consulting services related to our license revenue. Cost of services consists primarily of salaries, benefits, and allocated costs related to providing such services. Hardware revenue includes third party hardware used to support our software installations. Cost of hardware revenue consists of third party equipment and installation.

QuadraMed licenses its products through its direct sales force. The Company's license agreements for such products do not provide for a right of return, and historically, product returns have not been significant.

QuadraMed recognizes revenue on its software products in accordance with AICPA Statement of Position ("SOP") 97-2, *Software Revenue Recognition*, as amended by SOP 98-9, *Modification of SOP 97-2, Software Revenue Recognition, With Respect to Certain Transactions*; SOP 81-1, *Accounting for Performance of Construction-Type and Certain Production-Type Contracts*; and SEC Staff Accounting Bulletin ("SAB") 104, *Revenue Recognition*.

QuadraMed recognizes revenue when all of the following criteria are met: there is persuasive evidence of an arrangement; the product has been delivered; we no longer have significant obligations with regard to implementation; the fee is fixed and determinable; and collectability is probable. Delivery is considered to have occurred when title and risk of loss have been transferred to the customer, which generally occurs when media containing the licensed programs is provided to a common carrier. The Company considers all arrangements with payment terms extending beyond 180 days not to be fixed and determinable. Revenue for arrangements with extended payment terms is recognized when the payments become due, provided all other recognition criteria are satisfied. If collectability is not considered probable, revenue is recognized when the fee is collected.

QuadraMed allocates revenue to each element in a multiple-element arrangement based on the element's relative fair value, with the fair value determined by the price charged when that element is sold separately. Specifically, QuadraMed determines the fair value of the maintenance portion of the arrangement as if sold separately and measured by the renewal rate offered to the customer. The professional services portion of the arrangement is based on hourly rates which QuadraMed charges for these services when sold separately from software. If evidence of fair value of all undelivered elements exists but evidence does not exist for one or more delivered elements, then revenue is recognized using the residual method. Under the residual method, the fair value of the undelivered elements is deferred and the remaining portion of the arrangement fee is recognized as revenue. The proportion of revenue recognized upon delivery varies from quarter to quarter depending upon the mix of licensing arrangements, perpetual or term-based, and the determination of vendor-specific objective evidence ("VSOE") of fair value for undelivered elements. Many of our licensing arrangements include fixed implementation fees and do not allow us to recognize license revenue until these services have been performed. We recognize revenue only after establishing that we have VSOE for all undelivered elements.

Certain of the licenses are term or time-based licenses. QuadraMed recognizes revenue from these contracts ratably over the term of the arrangement.

Contract accounting is applied where services include significant software modification, installation or customization. In such instances, the services and license fee is accounted for in accordance with SOP 81-1, whereby the revenue is recognized, generally using the percentage-of-completion method measured on labor input hours. If increases in projected costs-to-complete are sufficient to create a loss contract, the entire estimated loss is charged to operations in the period the loss first becomes known. The complexity of the estimation process and judgment related to the assumptions, risks and uncertainties inherent with the application of the percentage-of-completion method of accounting can affect the amounts of revenue and related expenses reported in its consolidated financial statements.

Service revenues from software maintenance and support are recognized ratably over the maintenance term, which in most cases is one year. Service revenues from training, consulting and other service elements are recognized as the services are performed.

Hardware revenue is generated primarily from transactions in which customers purchased bundled solutions that included the Company's software and third party hardware. If the bundled solution includes services that provide significant modification, installation or customization, contract accounting is applied in accordance with SOP 81-1, whereby the revenue is recognized, generally using the percentage-of-completion method measured on labor input hours. Otherwise, hardware revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collection is reasonably assured.

Deferred revenue includes amounts billed to or received from customers for which revenue has not been recognized. This generally results from deferred maintenance, software installation, consulting and training services not yet rendered and license revenue deferred until all revenue requirements have been met or as services have been performed. Additionally, there are term-based licenses for which revenues are recognized over the term of the contract, which is generally one year. Unbilled receivables are established when revenue is deemed to be recognized based on QuadraMed's revenue recognition policy; however the Company does not have the right to bill the customer per the contract terms.

Cash and Cash Equivalents

Cash and cash equivalents consist of highly liquid investments that are comprised principally of taxable, short-term certificates of deposit, money market instruments and commercial paper with original maturities of three months or less at the time of purchase and demand deposits with financial institutions. These instruments carry insignificant interest rate risk because of their short-term maturities. Cash equivalents are stated at amounts that approximate fair value based on quoted market prices.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable consist primarily of amounts due to QuadraMed from its normal business activities. QuadraMed provides an allowance for doubtful accounts to reflect the expected non-collection of accounts receivable based on past collection history and specific risks identified.

Intangible Assets

QuadraMed's acquisitions of other companies typically result in the acquisition of certain intangible assets and goodwill.

Goodwill. QuadraMed adopted Statement of Financial Accounting Standards ("SFAS") No. 142, *Goodwill and Other Intangible Assets*, effective for fiscal years beginning after December 15, 2001, and ceased amortization of goodwill as of January 1, 2002. Prior to this point, goodwill was amortized using the straight-line method over its estimated useful life. Goodwill is subject to annual impairment tests or whenever changes in circumstances indicate that the fair value of the Company is less than the carrying value.

Capitalized Software. Software development costs are capitalized upon the establishment of technological feasibility, in accordance with SFAS No. 86, *Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed*. Upon the general release of the product to customers, development costs for that product are amortized over the greater of the ratio that current revenues bear to total and anticipated future revenues for the applicable product or the straight-line method, generally five years. These amounts are charged to cost of licenses. No amounts were capitalized in 2005 and 2004.

Other Intangible Assets. Other intangible assets primarily relate to acquired technology including developed and core technology, trade names and customer lists acquired in QuadraMed's purchase business combinations. Amortization of other intangible assets is computed on the basis of a 3-5 year life.

On an annual basis, QuadraMed reviews its intangible assets for impairment based on estimated future undiscounted cash flows attributable to the assets in accordance with the provisions of SFAS No. 144. In the event such cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their net realizable values.

NOTE 3. RECENT ACCOUNTING PRONOUNCEMENTS

In March 2004, the Financial Accounting Standards Board ("FASB") issued a proposed statement, "Share-Based Payment", which addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for equity instruments of the enterprise or liabilities that are based on the grant-date fair value of the enterprise's equity instruments or that may be settled by the issuance of such equity instruments. The proposed statement would eliminate the ability to account for share-based compensation transactions using Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees", and generally would require instead that such transactions be accounted for using a fair-value-based method. In December 2004, the FASB issued SFAS No. 123(R), *Share-Based Payment*, which is a revision of SFAS No. 123. Generally, the approach in SFAS No. 123(R) is similar to the approach described in SFAS No. 123. However, SFAS No. 123(R) requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their grant-date fair values. Pro forma disclosure is no longer an alternative.

As permitted by SFAS No. 123, the Company currently accounts for share-based payments to employees using APB Opinion No. 25's intrinsic value method and, as such, generally recognizes no compensation cost for employee stock options. Accordingly, the adoption of SFAS No. 123(R)'s fair value method may have a significant impact on the Company's result of operations as we will be required to recognize the cost of

employee services received in exchange for awards of equity instruments based on the grant-date fair value of those awards. The impact of adoption of SFAS No. 123(R) cannot be predicted at this time because it will depend on levels of share-based payments granted in the future. SFAS No. 123(R) permits public companies to adopt its requirements using either the “modified prospective” method or the “modified retrospective” method. The Company expects to adopt SFAS No. 123(R) using the modified-prospective method. In April 2005, the Securities and Exchange Commission delayed the effective date of SFAS No. 123(R), which is now effective for public companies for annual, rather than interim, periods that begin after June 15, 2005. The Company is currently evaluating the impact on its financial statements upon the adoption of SFAS No. 123(R), see Note 11.

In December 2004, the FASB issued SFAS No. 153, *Exchanges of Nonmonetary Assets*, which amends APB Opinion No. 29, *Accounting for Nonmonetary Transactions (SFAS No. 153)*, which requires a nonmonetary exchange of assets be accounted for at fair value, recognizing any gain or loss, if the exchange meets a commercial substance criterion and fair value is determinable. The commercial substance criterion is assessed by comparing the entity’s expected cash flows immediately before and after the exchange. This eliminates the “similar productive assets exception,” which accounts for the exchange of assets at book value with no recognition of gain or loss. SFAS No. 153 will be effective for nonmonetary asset exchanges occurring in fiscal periods beginning after June 15, 2005. We do not believe the adoption of SFAS No. 153 will have a material impact on our financial statements.

In March 2005, the FASB issued FIN 47, *Accounting for Conditional Asset Retirement Obligations, an interpretation of FASB Statement No. 143* (“FIN 47”), which requires an entity to recognize a liability for the fair value of a conditional asset retirement obligation when incurred if the liability’s fair value can be reasonably estimated. FIN 47 is effective for fiscal years ending after December 15, 2005. We do not anticipate that the adoption of FIN 47 will have a material impact on our financial statements.

In May 2005, the Financial Accounting Standards Board (“FASB”) issued SFAS No. 154, *Accounting Changes and Error Corrections*. SFAS No. 154 replaces APB No. 20, *Accounting Changes*, and SFAS No. 3, *Reporting Accounting Changes in Interim Financial Statements*, and establishes retrospective application as the required method for reporting a change in accounting principle. SFAS No. 154 provides guidance for determining whether retrospective application of a change in accounting principle is impracticable and for reporting a change when retrospective application is impracticable. The reporting of a correction of an error by restating previously issued financial statements is also addressed. SFAS No. 154 is effective for accounting changes and corrections of errors made in fiscal years beginning after December 15, 2005. We do not anticipate that the adoption of SFAS No. 154 will have a material impact on our financial statements.

NOTE 4. CLOSING AND DISCONTINUED OPERATION OF FINANCIAL SERVICES DIVISION

Due to increasing operating losses in our Financial Services Division, and the lack of a qualified buyer for the business, we announced the shutdown of this division on December 15, 2004, which was completed on February 14, 2005. In connection with the shutdown, we recorded an impairment charge of \$3.3 million in the fourth quarter of 2004, comprising severance expense of \$414,000, write-off of intangible assets of \$820,000, write-off of purchased software of \$1.85 million and write-off of leasehold improvement of \$246,000.

In the first nine months of 2005, the Company recorded a charge of approximately \$1.8 million in connection with our future obligations under the division’s San Marcos, California lease, net of estimated sublease income. The lease for this facility terminates in May 2008; our annual expense under the lease is approximately \$778,000, and we are actively seeking a qualified subtenant for the property. We have estimated the facility closing costs based upon current market information available related to potential sublease rental income, sublease commission costs, and the length of time expected to secure a sublease.

The results of operations for the Financial Services Division are presented as a discontinued operation in 2005. The Financial Services Division's operating results were as follows (in thousands):

	For the Nine Months Ended September 30,	
	2005	2004
Revenues	\$ 223	\$ 4,547
Loss from operation	(772)	(2,988)
Exit cost of facility closing	(1,849)	—
Other	118	—
Total loss	<u><u>\$(2,503)</u></u>	<u><u>\$(2,988)</u></u>

The following table sets forth a summary of the exit cost of facility closing, and the accrued facility cost as of September 30, 2005:

	For the Nine Months Ended September 30, 2005
Exit cost of facility closing accrued as of December 31, 2004	\$ 4,048
Add: exit cost of facility closing related to Financial Services Division as of February 2005	1,032
Add: Exit cost for facility closing of former headquarters	1,066
Add: Exit cost for facility closing related to Financial Services Division as of September 2005	817
Less: Payments made in the first nine months of 2005	<u>(1,074)</u>
Exit cost of facility closing accrued as of September 30, 2005	<u>\$ 5,889</u>
Short-term	1,868
Long-term	<u>4,021</u>
Total	<u><u>\$ 5,889</u></u>

The exit cost of facility closing accrued as of December 31, 2004 relates to the shut-down of our former headquarters in San Rafael, California. The Company estimated approximately \$4.0 million in connection with our future obligations on the lease, net of estimated sublease income, and recorded this expense in the fourth quarter of 2004. The short term portion of accrued exit cost of facility closing is included in the other accrued liabilities on the Consolidated Balance Sheets.

NOTE 5. REDUCTION IN FORCE

During the first quarter of fiscal year 2005, the Company announced a corporate reorganization and a reduction in our workforce of some 95 positions. The Company recorded a severance charge of \$531,000 related to terminated employees. As of September 30, 2005, approximately \$18,000 of this amount remains unpaid.

NOTE 6. GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill and other intangible assets for the nine-month period ended September 30, 2005 were as follows (in thousands):

	As of December 31, 2004	Q1 2005 Activity	Q2 2005 Activity	Q3 2005 Activity	As of September 30, 2005
Cost					
Capitalized software	\$ 13,445	\$ —	\$ —	\$ (402)	\$ 13,043
Goodwill	37,896	—	—	—	37,896
Other intangible assets	30,486	—	—	—	30,486
	<u>81,827</u>	<u>—</u>	<u>—</u>	<u>(402)</u>	<u>81,425</u>
Accumulated amortization					
Capitalized software	\$(12,018)	\$ (254)	\$ (243)	\$ 170	\$(12,345)
Goodwill	(11,913)	—	—	—	(11,913)
Other intangible assets	(18,035)	(1,362)	(1,349)	(1,327)	(22,073)
	<u>(41,966)</u>	<u>(1,616)</u>	<u>(1,592)</u>	<u>(1,157)</u>	<u>(46,331)</u>
Net book value					
Capitalized software	\$ 1,427	\$ (254)	\$ (243)	\$ (232)	\$ 698
Goodwill	25,983	—	—	—	25,983
Other intangible assets	12,451	(1,362)	(1,349)	(1,327)	8,413
	<u>\$ 39,861</u>	<u>\$(1,616)</u>	<u>\$(1,592)</u>	<u>\$(1,559)</u>	<u>\$ 35,094</u>

Amortization of acquired technology, a component of other intangible assets, for the three and nine months ended September 30, 2005 and 2004 was \$781,000, \$174,000 and \$2.3 million, \$543,000, respectively, and was included in cost of license revenue. There were no impairment charges recorded during the nine months ended September 30, 2005 or 2004.

NOTE 7. SERIES A PREFERRED STOCK

On June 17, 2004, QuadraMed issued 4.0 million shares of Series A Cumulative Mandatory Convertible Preferred Stock (the “Series A Preferred Stock”) in a private, unregistered offering to “qualified institutional buyers” pursuant to Rule 144A under the Securities Act of 1933. The Series A Preferred Stock was sold for \$25 per share, and QuadraMed used the \$96.1 million of net proceeds of the offering to repurchase all of our Senior Secured Notes due 2008 (the “2008 Notes”) and our 5.25% Convertible Subordinated 2005 Notes (the “2005 Notes”), together with accrued interest and related redemption premiums; the remainder was used for general corporate purposes.

The Series A Preferred Stock holders do not have any relative, participating, optional or other voting rights and powers, except that (i) if four quarterly dividend payments are in arrears, such holders are entitled to elect two substitute directors to the Board of Directors at any annual or special meeting, and (ii) in certain circumstances, such holders are entitled to vote on the authorization or creation of securities ranking on par with or above the Series A Preferred Stock, certain amendments to the Certificate of Incorporation or the Certificate of Designation for the Series A Preferred Stock, and the incurrence of new senior indebtedness in an aggregate principal amount exceeding \$8 million. Prior to the authorization or creation of, or increase in the authorized amount of, any shares of any class or series (or any security convertible into shares of any class or series) ranking senior to or on par with the Series A Preferred Stock in the distribution of assets upon any liquidation, dissolution or winding up of QuadraMed or in the payment of dividends, QuadraMed must have the affirmative vote of a majority of any outstanding shares of the Series A Preferred Stock (along with any shares of every other series or class of common stock ranking on par with the Series A Preferred Stock having like voting rights). In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, before any payment or distribution of the Company’s assets is made or set apart for the holders of common stock or any other class or series of shares of the Company’s capital stock ranking junior to the Series A Preferred Stock as to the payment

of dividends or as to the distribution of assets upon liquidation, dissolution or winding up, the holders of the Series A Preferred Stock shall be entitled to receive a liquidation preference of \$25 per share plus an amount equal to all dividends (whether or not earned or declared) accumulated, accrued and unpaid to the date of final distribution. However, for purposes of the foregoing provision, (1) a consolidation or merger of the Company with one or more entities, (2) a statutory share exchange or (3) a sale or transfer of all or substantially all of the Company's assets shall not be deemed to be a liquidation, dissolution or winding up of the Company.

The Series A Preferred Stock is entitled to quarterly dividends of \$0.34 (5.5% per annum) and is convertible into shares of common stock of the Company at a conversion price of \$3.10, equivalent to a conversion rate of 8.0645 shares of common stock for each share of Series A Preferred Stock. The initial conversion price of \$3.40 (conversion rate of 7.3529 shares of common stock for each share of Series A Preferred Stock) decreased to \$3.10 as of August 1, 2005, pursuant to the terms of the Certificate of Designation relating to the Series A Preferred Stock, as the volume weighted average of the daily market price per share during a period of 30 consecutive trading days equaled \$2.75 or less during the one year period beginning on the first anniversary of the issue date. Additionally, as provided in the Certificate of Designation, because the Company had not as of June 15, 2005, completed the registration of the Series A Preferred Stock with the SEC, the dividend rate for such stock increased to \$0.40625 per quarter (\$1.625 per annum) on June 16, 2005, and such rate will apply until the date the stock is registered. The Company has the right to demand conversion on or after May 31, 2007, in the event the volume weighted average of the daily market price per share during a period of 20 consecutive trading days equals or exceeds \$5.10.

Upon the conversion of shares of the Series A Preferred Stock to shares of common stock on or before May 31, 2007, the Series A Preferred Stock holders have an option to convert and receive, when declared by the board of directors, dividends equal to the total previously unpaid dividends payable from the effective date of conversion through June 1, 2007 at a rate of \$1.375 per annum, or 5.5% per annum, discounted to present value at a rate of 5.5% per annum, payable in cash or common shares or any combination thereof at the option of the Company.

As a result of the aforementioned feature, at the date of issuance of the Series A Preferred Stock, the Company recorded dividends payable of \$15.2 million, which represents the present value of the three-year dividends. The present value adjustment of \$1.3 million is being amortized over three years as interest expense using the effective interest rate method. For the nine month period ended September 30, 2005, approximately \$740,000 was recorded as interest expense.

The carrying value of the Series A Preferred Stock was also reduced by \$15.2 million, which represents the imputed discount on the Series A Preferred Stock and which is being accreted over three years using the effective interest rate method. For the nine months ended September 30, 2005, approximately \$3.6 million was accreted and charged to accumulated deficit. If any Series A Preferred Stock shares are converted prior to the end of the three-year period, the related accretion will be accelerated. The Company determined that there was no beneficial conversion feature attributable to the Series A Preferred Stock.

The following table summarizes the Series A Preferred Stock activities (in thousands):

	<u>As of September 30, 2005</u>
Total issued	\$100,000
Less: Issuance cost	(3,856)
Less: Unaccreted discount	
Original present value of discount	(15,174)
2005 preferred stock accretion	3,573
Prior preferred stock accretion	<u>2,465</u>
Carrying value of Preferred Stock at September 30, 2005	<u>\$ 87,008</u>

NOTE 8. LONG-TERM DEBT

In June 2004, the Company commenced, with net proceeds from the Series A Preferred Stock offering, a cash tender offer to purchase all of its outstanding 2008 Notes and 2005 Notes. In the quarter ended September 30, 2004, a principal balance of \$15.1 million of the 2008 Notes was retired with a premium of \$754,000 (5%) and a principal balance of \$11.9 million of the 2005 Notes was retired with a premium of \$89,000 (0.75%). As a result, the Company wrote off prorated portions of debt offering costs and the discount on the 2008 Notes and recorded a \$3.1 million loss on the retirement of Notes. In the quarter ended September 30, 2004, the Company retired the remaining \$58.8 million of the 2008 Notes and \$56,000 of the 2005 Notes. The total cash payment in July 2004 was \$63.2 million, which includes additional interest expense of \$54,000. Total loss recorded on the retirement of debt during the third quarter of 2004 was approximately \$11.7 million, which includes redemption premiums of \$2.9 million and write-offs of remaining balances of debt offering costs of \$577,000, the discount relative to the 2008 Notes of \$7.9 million, and the effective interest rate adjustment of \$339,000.

NOTE 9. RESTRICTED STOCK GRANTS

During the three and nine months ended September 30, 2005, 100,000 shares of common stock were issued as restricted stock grants. During the three and nine months ended September 30, 2004, zero and 50,000 shares of common stock were issued as restricted stock at no exercise price as provided for under QuadraMed's 1996 Stock Plan. The grants were made to certain senior executives for no monetary consideration. The majority of the Company's restricted shares fully vest over three to four years. QuadraMed has recorded the fair value of the restricted shares on the date they were granted as deferred compensation within the Stockholders' Equity section of the Consolidated Balance Sheets. This amount is amortized over the vesting period. Compensation expense associated with the grants of restricted stock total \$137,000 and \$226,000 during the three months ended September 30, 2005 and 2004 respectively, and \$420,000 and \$799,000 during the nine months ended September 30, 2005 and 2004, respectively. In addition to these amounts, \$1,442,000 was charged to severance expense in the nine months ended September 30, 2005 relating to the early-vesting of restricted stock issued to former officers of the Company.

As of September 30, 2005, 775,000 issued restricted shares remained unvested. On December 31, 2005, pursuant to the Company's Transition agreement with Lawrence P. English, its former Chief Executive Officer, the 675,000 shares of restricted stock owned by Mr. English will vest.

NOTE 10. NET LOSS PER SHARE AND COMPREHENSIVE LOSS

Basic loss per share is determined using the weighted average number of common shares outstanding during the period. Diluted loss per share is determined using the weighted average number of common shares and common equivalent shares outstanding during the period. Common equivalent shares consist of shares issuable upon the exercise of stock options and warrants (using the treasury stock method) and conversion of the Series A Preferred Stock and subordinated debentures (using the as-converted method). Common equivalent shares are excluded from the diluted computation if their effect is anti-dilutive.

The following table sets forth the computation of basic and diluted net loss per common share (in thousands):

	Three months ended September 30,	
	2005	2004
Numerator:		
Net loss attributable to common shareholders	\$ (5,165)	\$(17,639)
Denominator:		
Weighted average number of common shares outstanding basic and diluted	40,684	39,779
Basic and diluted net loss per common share	\$ (0.13)	\$ (0.44)

	<u>Nine months ended September 30,</u>	
	<u>2005</u>	<u>2004</u>
Numerator:		
Net loss attributable to common shareholders	\$(8,758)	\$(31,850)
Denominator:		
Weighted average number of common shares outstanding basic and diluted	40,407	34,621
Basic and diluted net loss per common share	\$ (0.22)	\$ (0.92)

As QuadraMed recorded net losses for both of the nine month periods ended September 30, 2005 and 2004, no common equivalent shares were included in diluted net loss per share calculation because they were anti-dilutive. If QuadraMed had reported net income, the calculation of diluted earnings per share would have included the following common stock equivalent shares from the indicated equity instruments (in thousands):

	<u>Nine months ended September 30,</u>	
	<u>2005</u>	<u>2004</u>
Equity instruments:		
Preferred stock	32,258	29,412
Warrants	3,265	3,273
Stock options	<u>658</u>	<u>1,775</u>
Total common stock equivalent shares	36,181	34,460

The components of QuadraMed's comprehensive loss include the unrealized gain (loss) on available-for-sale securities and foreign currency translation adjustment. The following table sets forth the computation of comprehensive loss (in thousands):

	<u>Nine months ended September 30,</u>	
	<u>2005</u>	<u>2004</u>
Net loss attributable to common shareholders	\$(8,758)	\$(31,850)
Unrealized loss	(44)	(39)
Foreign currency translation adjustment	<u>(2)</u>	<u>30</u>
Comprehensive loss	\$(8,804)	\$(31,859)

NOTE 11. STOCK-BASED COMPENSATION

SFAS No. 123, *Accounting for Stock Based Compensation*, encourages, but does not require, companies to record compensation cost for stock based employee compensation plans at fair value. QuadraMed has chosen to account for stock based employee compensation using the intrinsic value method prescribed in APB Opinion No. 25, *Accounting for Stock Issued to Employees, and Related Interpretations*. Accordingly, compensation cost for stock options granted to employees is measured as the excess, if any, of the quoted market price of QuadraMed's stock at the date of the grant over the amount an employee must pay to acquire the stock.

In December 2004, the FASB issued SFAS No. 123(R), *Share-Based Payment*, which is a revision of SFAS No. 123. SFAS No. 123(R) requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their grant-date fair values, using prescribed option-pricing models. Upon the adoption of SFAS No. 123(R) on January 1, 2006, pro forma disclosure is no longer an alternative. Accordingly, the adoption of SFAS No. 123(R)'s fair value method may have a significant impact on the Company's result of operations. The impact of adoption of SFAS No. 123(R) cannot be predicted at this time because it will depend on levels of share-based payments granted in the future. The stock-based compensation disclosure within this Note sets out the impact of using fair value accounting for share-based payments for the nine months ended September 30, 2005 and 2004. However, the amounts disclosed within our footnote are not

necessarily indicative of the amounts that will be expensed in future periods upon the adoption of SFAS No. 123(R). SFAS No. 123(R) also requires the benefits of tax deductions in excess of recognized compensation cost to be reported as a financing cash flow, rather than as an operating cash flow as required under current literature. This requirement will reduce net operating cash flows and increase net financing cash flows in periods after adoption.

In an effort to assess the impact of the adoption of SFAS No. 123(R), the Company has retained an independent consultant to assist in the determination of prescribed valuation criteria, evaluation of alternatives and analysis of core assumptions as required by the pronouncement.

QuadraMed has determined pro forma information regarding net income and earnings per share as if we had accounted for employee stock options under the fair value method as required by SFAS No. 123. The fair value of these stock-based awards to employees was estimated using the Black-Scholes option pricing model. Had compensation cost for the Company's stock option plan and employee stock purchase plan been determined consistent with SFAS No. 123, the Company's reported net loss and net loss per share would have been changed to the amounts indicated below (in thousands except per share data):

	Three months ended September 30,	
	2005	2004
Net loss attributable to common shareholders, as reported	\$ (5,165)	\$(17,639)
Add: Stock-based employee compensation expense in reported net loss	139	266
Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards,	<u>(563)</u>	<u>(1,380)</u>
Pro forma net loss	<u>\$ (5,589)</u>	<u>\$(18,753)</u>
Basic and diluted net loss per common share, as reported	\$ (0.13)	\$ (0.44)
Basic and diluted net loss per common share, pro forma	\$ (0.14)	\$ (0.47)

	Nine months ended September 30,	
	2005	2004
Net loss attributable to common shareholders, as reported	\$ (8,758)	\$(31,850)
Add: Stock-based employee compensation expense in reported net income (loss)	1,030	1,236
Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards,	<u>(2,497)</u>	<u>(4,530)</u>
Pro forma net loss	<u>\$(10,225)</u>	<u>\$(35,144)</u>
Basic and diluted net loss per common share, as reported	\$ (0.22)	\$ (0.92)
Basic and diluted net loss per common share, pro forma	\$ (0.25)	\$ (1.02)

The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following assumptions:

	2005	2004
Expected dividend yield	—	—
Expected stock price volatility	151.30%	119.40%
Risk-free interest rate	3.93%	3.41%
Expected life of options	3.47 years	4.28 years

The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following assumptions:

NOTE 12. ADDITIONAL INFORMATION AS TO CERTAIN REVENUE AND EXPENSES

Included as a component of operating expenses for the three and nine months ended September 30, 2005 and 2004 are the following items (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2005	2004	2005	2004
Settlement of litigation	\$ —	\$ —	\$ (700)	\$ —
Legal fees related to shareholder litigation	—	(127)	—	(807)
Life insurance proceeds	—	—	532	—
Insurance reimbursement	—	—	407	—
Mergers and acquisition costs	166	—	(406)	—
Executive stock expense for former officer	(850)	—	(1,442)	—
Severance costs and retention bonuses	(2,426)	—	(2,957)	(842)
Loss on lease obligations	(1,883)	—	(1,883)	—
Office relocation costs	—	—	—	(365)
Total	<u>\$(4,993)</u>	<u>\$(127)</u>	<u>\$(6,449)</u>	<u>\$(2,014)</u>

NOTE 13. MAJOR CUSTOMERS

No single customer accounted for more than 10% of total revenues in the three and nine months ended September 30, 2005. In the three and nine months ended September 30, 2004, one single customer, Micron Government Computer Systems, (“Micron”) accounted for 11% and 10% of total revenues respectively.

NOTE 14. LITIGATION AND OTHER MATTERS

On July 6, 2005, the Company settled its litigation with Mr. James Durham, its former Chief Executive Officer. Under the terms of the Settlement Agreement and General Release (“Settlement Agreement”) between the parties, the Company made an immediate cash payment of approximately \$3.6 million to Mr. Durham and issued a Negotiable Promissory Note (the “Note”) to Mr. Durham in the principal amount of \$1.4 million and with an interest rate of 5.12% per annum. The timing of payments under the Note is linked to the Company’s realization of amounts invested in a split-dollar insurance arrangement (the “Split-Dollar Policy”) with Mr. Durham. As of September 30, 2005, the Company has fully accrued for the payment. The immediate payment of \$3.6 million was funded principally by the liquidation of certain assets earmarked for such purpose, in the amount of \$3.1 million, and payment of \$0.5 million out of operating cash. The Company’s obligations under the Note are secured by a collateral assignment of the Company’s rights under the Split-Dollar Policy and certain related agreements. The Settlement Agreement includes various releases from both parties.

On November 15, 2004, the Company received a letter from MedCath Incorporated (“MedCath”), which provided notice of MedCath’s decision to terminate the Master Software License and Services Agreement, dated November 20, 2002, by and between QuadraMed Affinity and MedCath (the “Contract”). On or about November 15, 2004, MedCath filed a complaint against us in the North Carolina Superior Court, County of Mecklenburg. In its complaint, MedCath alleges that we are in breach of the Contract due to uncured deficiencies in the products, and seeks at least \$5 million in damages, plus litigation costs. We believe that these allegations are without merit and that the termination of the Contract is unwarranted. On December 9, 2004, we filed a motion to dismiss the MedCath complaint on the grounds that the complaint fails to state a claim upon which relief can be granted. We also filed a counterclaim against MedCath seeking no less than \$1.14 million in unpaid amounts due to us, plus litigation costs, for MedCath’s breach of the Contract by failing to pay licensing fees due to the Company. A case management conference was held July 29, 2005 in the Superior Court before a judge to whom the case has been assigned. On August 15, 2005, the Court issued a case management order which, among other things, provides for all fact discovery to be completed by April 15, 2006, provides for all expert discovery to be completed by July 15, 2006, and provides for the parties to submit the dispute to mediation on or before April 30, 2006. On October 19, 2005, the Court issued an order denying our motion to dismiss. We will continue to defend ourselves vigorously against any claim that we have breached the Contract and will seek redress through all applicable remedies for any injuries suffered by the Company in connection with this matter.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Statement on Risks Associated With Forward-Looking Statements

You should read the following discussion in conjunction with our Condensed Consolidated Financial Statements and related notes. This Report contains forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are subject to risks and uncertainties. The words "believe", "expect", "target", "goal", "project", "anticipate", "predict", "intend", "plan", "estimate", "may", "will", "should", "could", and similar expressions and their negatives are intended to identify such statements. Forward-looking statements are not guarantees of future performance, anticipated trends and growth in businesses, or other characterizations of future events or circumstances and are to be interpreted only as of the date on which they are made. We undertake no obligation to update or revise any forward-looking statement. You should not place undue reliance on these forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks faced by us described below and elsewhere in this Report, and in other documents we file with the SEC from time to time.

Results of Operations (unaudited)

The following table sets forth selected data for the indicated periods. Percentages are expressed as a percentage of total revenues, except for cost of revenue, which is expressed as a percentage of the related revenue classification.

	Three months ended September 30,			
	2005		2004	
Revenue				
Services	\$ 2,824	9%	\$ 2,924	10%
Maintenance	13,767	46%	12,839	42%
Installation and other	3,196	11%	3,276	11%
Services and other	19,787	66%	19,039	62%
Licenses	10,009	33%	9,562	31%
Hardware	250	1%	2,175	7%
Total revenue	<u>30,046</u>	<u>100%</u>	<u>30,776</u>	<u>100%</u>
Cost of revenue				
Cost of services and other	7,326	37%	7,670	40%
Royalties and other	2,385	24%	2,173	23%
Amortization of acquired technology and capitalized software	1,014	10%	791	8%
Cost of licenses	3,399	34%	2,964	31%
Cost of hardware	682	273%	1,829	84%
Total cost of revenue	<u>11,407</u>	<u>38%</u>	<u>12,463</u>	<u>40%</u>
Gross margin	<u>18,639</u>	<u>62%</u>	<u>18,313</u>	<u>60%</u>
Operating expenses				
General and administration	8,340	28%	7,765	25%
Software development	7,812	26%	7,137	23%
Sales and marketing	3,160	11%	5,962	19%
Amortization of intangible assets and depreciation	1,087	4%	1,106	4%
Loss on lease Obligation	1,066	4%	—	0%
Total operating expenses	<u>\$21,465</u>	<u>71%</u>	<u>\$21,970</u>	<u>71%</u>
Loss from operations	<u>\$ (2,826)</u>		<u>\$ (3,657)</u>	

	<u>Nine months ended September 30,</u>			
	<u>2005</u>		<u>2004</u>	
Revenue				
Services	\$ 9,448	10%	\$ 8,947	9%
Maintenance	41,152	45%	36,149	38%
Installation and other	8,300	9%	9,837	10%
Services and other	58,900	65%	54,933	57%
Licenses	30,143	33%	33,236	35%
Hardware	2,061	2%	7,723	8%
Total revenue	<u>91,104</u>	<u>100%</u>	<u>95,892</u>	<u>100%</u>
Cost of revenue				
Cost of services and other	21,764	37%	22,976	42%
Royalties and other	6,811	23%	7,637	23%
Amortization of acquired technology and capitalized software	3,073	10%	2,142	6%
Cost of licenses	9,884	33%	9,779	29%
Cost of hardware	2,190	106%	5,435	70%
Total cost of revenue	<u>33,838</u>	<u>37%</u>	<u>38,190</u>	<u>40%</u>
Gross margin	<u>57,266</u>	<u>63%</u>	<u>57,702</u>	<u>60%</u>
Operating expenses				
General and administration	20,625	23%	24,328	25%
Software development	23,253	26%	21,082	22%
Sales and marketing	10,727	12%	17,787	19%
Amortization of intangible assets and depreciation	3,793	4%	3,132	3%
Loss on lease Obligation	1,066	1%	—	0%
Total operating expenses	<u>\$59,464</u>	<u>65%</u>	<u>\$66,329</u>	<u>69%</u>
Income (loss) from operations	<u>\$ (2,198)</u>		<u>\$ (8,627)</u>	

Revenue

Total revenue. Total revenues for the three months ended September 30, 2005 were \$30.0 million, a decrease of \$0.8 or 2.6% from \$30.8 million for the three months ended September 30, 2004. HIM revenues increased \$1.8 million in the three months ended September 30, 2005 compared with the same period in 2004 due to an increase in license and installation revenue. In the three months ended September 30, 2005 Enterprise product revenues decreased by \$2.2 million compared to the three months ended September 30, 2004 due to a \$1.9 million decrease in hardware revenues, an \$0.8 million decrease in license revenues, and a \$0.5 million decrease in installation revenues which were partially offset by a \$1.1 million increase in maintenance revenue. In the three months ended September 30, 2005 Government product revenues decreased by \$0.2 million compared to the three months ended September 30, 2004 due to a decrease in installation and training revenues.

Total revenues for the nine months ended September 30, 2005 were \$91.1 million, a decrease of \$4.8 million or 5.0% from \$95.9 million for the nine months ended September 30, 2004. There was a \$5.4 million decrease in Affinity hardware revenue in 2005. Total revenue for the same period in the prior year included approximately \$3.8 million in hardware revenue related to one customer. The 2004 acquisitions of Tempus and Détente contributed \$5.4 million to revenue in 2005 compared to \$2.6 million in 2004.

Services and other. Services and other revenue consists of professional services, such as implementation and installation services, training, maintenance, which consists of technical support and product upgrades, reimbursable expenses and other services revenue. Professional services are typically provided over a period of

three to nine months for the HIM product solutions and two to three years for Affinity and other related Enterprise products. These services are provided subsequent to the signing of a software license agreement and depend almost exclusively on our software license revenue. Our maintenance revenue depends on both licenses of our software products and renewals of maintenance agreements by our existing customer base and are recognized ratably over the term of the agreement.

Services revenue of \$2.8 million, or 9.4% of total revenue in the three months ended September 30, 2005 decreased \$0.1 million, or 3.4%, from \$2.9 million in the same period last year.

Services revenue of \$9.4 million, or 10.0%, of total revenue in the nine months ended September 30, 2005 increased \$0.5 million, or 5.6%, from \$8.9 million in the same period last year. The increase in revenue of \$0.5 million, mainly related to the growth in supplemental services provided to our existing Affinity customers, and an increase in service revenue in the MPI Services business. These increases were offset by a \$0.4 million decline in service related work in PFS.

Maintenance revenue was \$13.8 million in the three months ended September 30, 2005 compared to \$12.8 million in the three months ended September 30, 2004, representing an increase of \$1.0 million or 7.2%. Maintenance revenue, as a percentage of total revenue, was 45.8% and 41.7% in the three months ended September 30, 2005 and 2004, respectively. The increase in maintenance revenue is mainly due to increased number of contracts and periodic increases in rates, particularly in the Enterprise products.

Maintenance revenue was \$41.1 million in the nine months ended September 30, 2005 compared to \$36.1 million in the nine months ended September 30, 2004, representing an increase of \$5.0 million or 13.8%. Maintenance revenue, as a percentage of total revenue, was 45.2% and 37.7% in the nine months ended September 30, 2005 and 2004, respectively. The increase in maintenance revenue is mainly due to increased number of contracts and periodic increases in rates, particularly in the Enterprise products and \$2.4 million in additional maintenance revenue from the Tempus acquisition.

Installation and other services revenue decreased to \$3.2 million in the three months ended September 30, 2005 from \$3.3 million in the three months ended September 30, 2004. The installation revenue decrease is primarily due to a decrease in revenue from Affinity and other Enterprise products partially offset by an increase in HIM installation revenues in the period.

Installation and other services revenue decreased to \$8.3 million in the nine months ended September 30, 2005 from \$9.8 million in the nine months ended September 30, 2004. The installation and other service revenue decrease is primarily due to a decrease in revenue from Affinity and other Enterprise products partially offset by an increase in HIM and government installation revenues in the period.

Licenses. License revenue consists of fees and licenses of proprietary and third party software, all of which is marketed through our direct sales force. License revenue in the three months ended September 30, 2005 was \$10.0 million, an increase of \$0.4 million or 4.7% from \$9.6 million in the corresponding period of 2004. License revenue, as a percentage of total revenue, was 33.3% and 31.1% in the three months ended September 30, 2005 and 2004, respectively. License revenue for Enterprise products decreased by approximately \$0.8 million to \$3.8 million in the three months ended September 30, 2005 from \$4.6 million in the same quarter prior year. Affinity license revenue declined by \$0.4 million from the third quarter of 2004 due to the completion of many contracts in 2004. License revenue for HIM products increased by \$1.2 million in the three months ended September 30, 2005 to \$3.6 million or 33.9% in the three months ended September 30, 2005 due to the completion of many contracts during the current quarter.

License revenue in the nine months ended September 30, 2005 was \$30.1 million, a decrease of \$3.1 million or 9.3% from \$33.2 million in the corresponding period of 2004. License revenue, as a percentage of total revenue, was 33.1% and 34.7% in the nine months ended September 30, 2005 and 2004, respectively. License

revenue for Enterprise products decreased by approximately \$5.4 million to \$12.1 million in the nine months ended September 30, 2005 from \$17.5 million in the same period prior year. The decrease in Enterprise license revenue was the result of a decrease in new Affinity contracts and a reduction in revenue from PFS contracts. However, HIM license revenues increased \$2.3 million to \$10.0 million in the nine months ended September 30, 2005 from \$7.7 million in the same period prior year. Government license revenue increased \$0.2 million to \$8.1 million in the nine months ended September 30, 2005 compared to \$7.9 million in the nine months ended September 30, 2004.

Hardware. Hardware revenue consists of the sale of third party hardware purchased specifically for use by our customers. Hardware revenue decreased \$1.9 million to \$0.3 million in the three months ended September 30, 2005 from \$2.2 million in the three months ended September 30, 2004. Hardware revenue, as a percentage of total revenue, was 0.8% and 7.1% in the three months ended September 30, 2005 and 2004, respectively.

Hardware revenue in the nine months ended September 30, 2005 was \$2.1 million, a 73.3% decrease from \$7.7 million in the nine months ended September 30, 2004. In the first quarter of 2004 the Company completed a significant Affinity contract which was signed at the end of fiscal year 2003 and resulted in a one-time increase in hardware revenue.

Revenue recognized for the three and nine months ended September 30, 2005 and 2004 includes:

- amounts initially recorded as deferred revenue in which the Company has now completed its contractual commitments;
- service revenue relating to installation and training, during the period; and
- revenues recognized on a cash-basis after the Company's contractual commitment has been completed.

The following table is a summary roll forward schedule of deferred revenue (in thousands):

	For the Three Months Ended September 30,	
	2005	2004
Deferred revenue, beginning balance	\$ 52,436	\$ 50,325
Add: revenue deferred	26,672	20,658
Less: deferred revenue recognized	(29,083)	(25,511)
Deferred revenue, ending balance	<u>\$ 50,025</u>	<u>\$ 45,472</u>
	For the Nine Months Ended September 30,	
	2005	2004
Deferred revenue, beginning balance	\$ 44,040	\$ 48,502
Add: revenue deferred	93,699	77,696
Less: deferred revenue recognized	(87,714)	(83,492)
Add: revenue acquired in acquisition	—	2,766
Deferred revenue, ending balance	<u>\$ 50,025</u>	<u>\$ 45,472</u>

Cost of Revenue

Cost of services and other. Cost of services and other consists of salaries and related expenses associated with services performed for customer support, installation, maintenance and consulting services. Cost of services and other for the quarter ended September 30, 2005 of \$7.3 million was \$0.4 million less than the \$7.7 million in the corresponding period of 2004. As a percentage of services and other revenue, cost of services and other was 37.1% and 40.3% for the three months ended September 30, 2005 and 2004, respectively. The decrease was primarily due to a decrease in non-wage related costs.

Cost of services and other for the nine months ended September 30, 2005 of \$21.8 million was \$1.2 million less than the \$23.0 million in the corresponding period of 2004. As a percentage of services and other revenue, cost of services and other was 37.0% and 41.8% for the nine months ended September 30, 2005 and 2004, respectively. The decrease was primarily due to a decrease in personnel and non-wage costs.

Cost of licenses. Cost of licenses consists primarily of the cost of third party software, royalties and amortization of capitalized software and acquired technology. A significant percentage of our total cost of revenue is attributable to the cost of third party software royalties and licenses relating to software embedded within our software applications. Generally, third party royalty fees fluctuate based on revenue or the number of the Company's customers and therefore will fluctuate on a quarter to quarter basis. Cost of licenses in the three months ended September 30, 2005 of \$3.4 million, increased \$0.4 million compared to \$3.0 million for the same period of 2004. As a percentage of license revenue, cost of licenses was 34.0% and 31.0% for the three months ended September 30, 2005 and 2004, respectively.

Cost of licenses in the nine months ended September 30, 2005 of \$9.9 million, increased \$0.1 million compared to \$9.8 million for the same period of 2004. Acquired software amortization costs increased \$1.7 million and costs of third party royalties increased by \$0.5 million. These cost increases were offset by a \$2.1 million decrease in cost of third party software licenses and other expenses. As a percentage of license revenue, cost of licenses was 32.9% and 29.4% for the nine months ended September 30, 2005 and 2004, respectively.

Cost of hardware. Cost of hardware consists of third party hardware and installation costs. Cost of hardware in the three months ended September 30, 2005 was \$0.7 million, a decrease of \$1.1 million compared to \$1.8 million for the same period last year.

During the nine months ended September 30, 2005 cost of hardware was \$2.2 million, a decrease of \$3.2 million, compared to \$5.4 million for the same period last year. Cost of hardware in the first quarter of 2004 was unusually high due to a large hardware sale to a single Affinity customer, the revenue for which was also recorded in that period.

Gross Margin

Overall, gross margin increased to 62% for the three months ended September 30, 2005 from 59.5% for the same period in 2004. Gross margin on license revenue declined to 66.0% in the three months ended September 30, 2005 from 69.0% in the three months ended September 30, 2004. Gross margin on services and other revenue improved from 59.7% to 62.9% due to increased maintenance revenue and the 2005 reorganization, resulting in decreased costs. The margin on hardware revenue declined from 15.9% to a negative percentage in the three month period ending September 30, 2005. This is due primarily to certain adjustments to hardware revenue and hardware expense resulting from related account reconciliations in the current quarter.

Overall, gross margin improved from 60.2% for the nine months ended September 30, 2004 to 62.9% for the nine month period ended September 30, 2005. Gross margin on license revenue declined from 70.6% to 67.2% for the respective periods due to increased amortization of acquired technology in 2005 that resulted from the 2004 acquisitions of D tente and Tempus and additional third party license and royalty costs. Gross margin on services and other revenue improved from 58.2% to 63.0% due to increased maintenance revenue and the 2005 reorganization, resulting in decreased costs. The margin on hardware revenue declined to a negative percentage in the nine months ended September 30, 2005. This is due primarily to certain adjustments to hardware revenue and hardware expense resulting from related account reconciliations in the current quarter. In addition, the relatively high 29.6% margin experienced for the nine months ended September 30, 2004 was due to a significant level of hardware revenue in the first quarter of 2004, which was almost all from a single contract, and which was unusually profitable.

Operating Expenses

General and administration. General and administration expense consists of compensation and benefit costs for executive, finance, legal, information technology, and administrative personnel. General and administration expense increased to \$8.3 million in the third quarter of 2005 compared to \$7.8 million in the same quarter in the prior year. As a percentage of total revenue, general and administration expense was 28.8% and 25.2% for the three month periods ended September 30, 2005 and 2004, respectively. The overall \$0.5 million increase is mainly attributable to \$2.9 million increase in severance expense offset by \$1.0 million decrease in wages and related costs, a decrease in bad debt expense of \$0.2 million, and a \$0.8 million decrease in rent and other related common expenses assigned to administrative departments. In addition, the \$0.4 million gain on sale of the EDI division is included in the 2005 period.

For the nine months ended September 30, 2005, general and administration expense decreased to \$20.6 million compared to \$24.3 million in the same period in the prior year. As a percentage of total revenue, general and administration expense was 23.0% and 25.4%, respectively for the periods. The overall \$3.7 million decrease is mainly attributable to decreased wages and related costs of \$2.6 million, a decrease in bad debt expense of \$1.2 million, a \$2.4 million decrease in rent and other related common expenses assigned to administrative departments, all offset by \$2.1 million net increase in severance costs. In addition, the \$0.4 million gain on the sale of the EDI division is included in the 2005 period.

Software development. Software development expense includes costs associated with the development of new products for which technological feasibility has not been achieved, enhancements of existing products, maintenance and quality assurance activities and primarily relates to compensation and benefits costs. Software development costs, in the three months ended September 30, 2005 were \$7.8 million compared to \$7.1 million in the same period in 2004, representing an increase of \$0.7 million. As a percentage of total revenue, software development costs were 26.0% and 23.2% for the quarters ended September 30, 2005 and 2004, respectively. The increase was primarily attributed to a \$0.2 million increase in severance costs and an increase in personnel costs.

Software development costs, in the nine months ended September 30, 2005 were \$23.3 million compared to \$21.1 million in the same period in 2004, representing an increase of \$2.2 million. As a percentage of total revenue, software development costs were 25.5% and 22.0% for the nine months ended September 30, 2005 and 2004, respectively. The increase was primarily attributed to a \$0.4 million increase in severance costs, an increase in personnel costs and overall expenses for software development departments, attributable in part to such expenses at D tente and Tempus, which were acquired during 2004.

Sales and marketing. Sales and marketing expense includes costs associated with our sales and marketing personnel and consists primarily of compensation and benefits, commissions and bonuses, promotional and advertising expenses. Sales and marketing expense decreased \$2.8 million in the three months ended September 30, 2005 to \$3.2 million from \$6.0 million in the same period last year. As a percentage of total revenue, sales and marketing expenses decreased to 10.5% in the three months ended September 30, 2005 from 19.4% in the

same period of 2004. This was primarily due to a decrease in commissions of \$1.4 million, a decrease in other wage related expenses of \$1.0 million, and a decrease in travel expense of \$0.4 million. Salaries and wages decreased primarily as a result of the January 2005 reorganization and realignment of personnel.

Sales and marketing expense decreased \$7.1 million in the nine months ended September 30, 2005 to \$10.7 million from \$17.8 million in the same period last year. As a percentage of total revenue, sales and marketing expenses decreased to 11.8% in the nine months ended September 30, 2005 from 18.5% in the same period of 2004. This was primarily due to a decrease in commissions of \$3.4 million, a decrease in other wage related expenses of \$2.5 million, a decrease in travel expense of \$0.9 million, and a decrease in advertising expenses of \$0.3 million. Salaries and wages decreased primarily as a result of the January 2005 reorganization and realignment of personnel.

In the three months ended September 30, 2005, the company recorded a \$1.1 million loss on the San Rafael office lease. This is in addition to the initial \$4.0 million loss it recorded in 2004. The overall market conditions, lack of qualified subtenants, type of property, and the passage of time are all contributing factors to the revision to the estimated sublease income stream for the property. The lease terminates in December, 2009 and the Company will continue to make lease payments under the terms and conditions of its lease until a sublease arrangement is secured.

Amortization of intangible assets and depreciation. Amortization of intangible assets and depreciation expense were flat at \$1.1 million for the three months ended September 30, 2005 and 2004, respectively. For the nine months ended September 30, 2005, amortization of intangible assets and depreciation expense increased to \$3.8 million from \$3.1 million in the corresponding period in 2004.

Other Income (Expense)

Other income (expense), net. Net other expense was \$0.3 million in the three months ended September 30, 2005 compared to expense of \$11.9 million in the corresponding quarter in 2004 and \$0.5 million expense and \$18.9 million expense for the nine months ended September 30, 2005 and 2004 respectively. The decrease was primarily due to the \$14.9 million loss on the retirement of debt in mid 2004. Interest expense for the quarters ended September 30, 2005 and 2004 was \$0.4 million and \$0.3 million, respectively. Interest expense for the nine months ended September 30, 2005 and 2004 was \$4.7 million and \$0.8 million, respectively.

Discontinued Operations of Financial Services Division

Due to increasing operating losses in our Financial Services Division, and the lack of a qualified buyer for the business, we announced the shutdown of this division on December 15, 2004. The shutdown of this division was effective February 15, 2005. In connection with the shutdown, we recorded an impairment charge of \$3.3 million in the fourth quarter of 2004, comprising severance expense of \$0.4 million, write-off of intangible assets of \$0.8 million, write-off of purchased software of \$1.9 million and write-off of leasehold improvement of \$0.2 million.

During the nine months ended September 30, 2005, the Company recorded a charge of approximately \$1.8 million in connection with our future obligations on the Division's San Marco, California lease, net of estimated sublease income. The lease for this facility terminates in May 2008; our annual expense under the lease is approximately \$0.8 million, and we are actively seeking a qualified subtenant for the property. We have estimated facility closing costs based upon current market information available related to potential sublease rental income, sublease commission costs, and the length of time expected to sublease to secure a sublease.

The results of operations for Financial Services Division are presented as discontinued operations. Loss from discontinued operations of the Financial Services Division were comprised of the following items (in thousands):

	For the Three Months Ended September 30,	
	2005	2004
Revenue	\$ —	\$ 1,295
Loss from operations	—	(748)
Exit cost of facility closing	(817)	—
Other	—	—
Total loss	<u>\$ (817)</u>	<u>\$ (748)</u>

	For the Nine Months Ended September 30,	
	2005	2004
Revenue	\$ 223	\$ 4,547
Loss from operations	(772)	(2,988)
Exit cost of facility closing	(1,849)	—
Other	118	—
Total loss	<u>\$(2,503)</u>	<u>\$(2,988)</u>

Liquidity and Capital Resources

Balance Sheet

As of September 30, 2005, we had \$34.0 million in cash, cash equivalents and short-term investments, compared to \$22.4 million as of December 31, 2004. As of September 30, 2005, our working capital was (\$9.6) million compared to (\$15.1) million as of December 31, 2004. Our working capital deficiency of \$9.6 million is primarily a result of \$50.0 million of deferred revenue (liability) and \$10.3 million of dividends payable. The dividends payable represent the remaining unpaid portion of the three year \$15.2 million dividend payable that was recorded when the Series A Preferred stock was issued in 2004. We have the option to pay the accelerated dividends, as discussed in Note 7, in cash or common stock. We do not have any bank borrowing outstanding at September 30, 2005. We believe that we have adequate liquidity to meet our short-term cash requirements.

Accounts receivable increased by \$0.5 million to \$26.1 million as of September 30, 2005 from \$25.6 million as of December 31, 2004 on a net basis. For the nine months ended September 30, 2005, bad debt expense was \$1.8 million and the write-offs of uncollectible receivables totaled approximately \$0.6 million. As of September 30, 2005, the allowance for doubtful accounts increased to \$4.6 million from \$3.3 million as of December 31, 2004. QuadraMed maintains an allowance for doubtful accounts to reflect the expected non-collection of accounts receivable based on past collection history and specific risks identified within the portfolio. If the financial condition of QuadraMed's customers were to deteriorate resulting in an impairment of their ability to make payments, or if payments from customers are significantly delayed, additional allowance might be required.

Prepaid expenses and other current assets increased by approximately \$1.4 million from December 31, 2004 to September 30, 2005 primarily due to an increase in deferred cost of goods sold, offset by a decrease in maintenance costs.

Accounts payable and accrued expenses decreased by \$0.5 million to \$4.0 million at September 30, 2005 from \$4.5 million at December 31, 2004 principally due to timing of payments made after year-end. Certain third party royalty and legal invoices were accrued as of December 31, 2004 but paid subsequent to year-end.

Accrued payroll and related expenses increased by \$2.0 million to \$9.6 million at September 30, 2005 from \$7.6 million at December 31, 2004 principally due to increases in accrued severance and incentive bonus plans offset by decreases in accrued vacation and accrued medical insurance.

Deferred revenue increased by \$6.0 million from \$44.0 million at December 31, 2004 to \$50.0 million at September 30, 2005. The increase was primarily related to annual maintenance billings that occurred in the first three quarters of the current fiscal year for our Enterprise products.

Cash Flows

The Company's consolidated statement of cash flows is summarized below (in thousands):

	<u>For the Three Months Ended September 30,</u>	
	<u>2005</u>	<u>2004</u>
Cash provided by (used in) operating activities	\$ 6,040	\$ (2,027)
Cash provided by (used in) investing activities	157	(1,231)
Cash provided by (used in) financing activities	(1,219)	(62,110)
Net increase in cash and cash equivalents	4,978	(65,368)
	<u>For the Nine Months Ended September 30,</u>	
	<u>2005</u>	<u>2004</u>
Cash provided by (used in) operating activities	\$14,143	\$ (9,718)
Cash provided by (used in) investing activities	783	(11,017)
Cash provided by (used in) financing activities	(3,363)	9,823
Net increase in cash and cash equivalents	11,563	(10,912)

During the three months ended September 30, 2005, \$6.0 million was provided in operating activities, as compared to the same period last year where \$2.0 million was used in operating activities. The net loss of \$5.2 million was reduced by non-cash charges totaling \$7.1 million, including depreciation and amortization of \$3.5 million, bad debt expense of \$0.9 million, preferred stock accretion of \$1.2 million, additional loss on lease obligations of \$0.8 million for the Financial Services Division and \$1.1 million of additional loss on the lease obligation for the former headquarters building; these items are partially offset by a \$0.4 million gain on the sale of the EDI division. A decrease in accounts receivable resulted in increased cash from operating activities by \$4.4 million. This was principally a result of strong collection efforts during the period. A decrease of \$1.7 million related prepaid expenses and other contributed to the cash provided by operations. Increases in accounts payable and accrued liabilities during the quarter of \$0.3 million further increased cash from operations due primarily to the timing of future severance payments. These increases were offset in part by a \$2.3 million decrease in deferred revenues. During the three months ended September 30, 2004, the \$2.0 million of cash flow used in operating activities, resulted primarily from a net loss of \$17.6 million, reduced by \$2.4 million of depreciation and amortization, \$12.6 million of loss on retirement of debt, \$1.9 million of bad debt expense. An increase of \$2.4 million in accounts payable and accrued liabilities, and a net \$1.2 million decrease in accounts receivable and prepaid expenses offset by a \$4.9 million decrease in deferred revenue.

During the nine months ended September 30, 2005, \$14.1 million was provided in operating activities, as compared to the same period last year where \$9.7 million was used in operating activities. The net loss of \$8.8 million was offset by non-cash charges totaling \$17.2 million, including depreciation and amortization of \$9.5 million, bad debt expense of \$1.7 million, preferred stock accretion of \$3.6 million, and \$1.7 million related to additional loss on lease obligations, costs for the Financial Services Division, and \$1.1 million of additional loss on the lease obligation for the former headquarters building. An increase in accounts receivable resulted in decreased cash from operating activities by \$2.2 million. This was principally a result of the timing of annual maintenance billings during the period. Decreases in prepaid and other expenses of \$4.7 million and a \$6.0 million increase in deferred revenue offset by a decrease in accounts payable and accrued liabilities during the nine months of \$2.9 million resulted in increased cash from operations. During the nine months ended September 30, 2004, \$9.7 million

was used in operating activities. The net loss of \$31.9 million was reduced by non-cash charges totaling approximately \$25.9 million, including depreciation and amortization of \$8.0 million, bad debt expense of \$3.0 million, and loss on retirement of debt of \$14.9 million. A decrease in accounts receivable increased cash from operating activities by \$4.7 million and a decrease in prepaid and other assets increased cash by \$1.0 million. Accounts payable and accrued liabilities and deferred revenue used \$3.7 million and \$5.8 million, respectively.

Cash flows from investing activities provided \$0.2 million during the three months ended September 30, 2005, as a net result of cash proceeds from the sale of our EDI division offset by capital expenditure. For the three months ended September 30, 2004, \$1.2 million was used for investing purposes primarily due to capital expenditures.

Cash used in investing activities of \$0.8 million during the nine months ended September 30, 2005, was the result of capital expenditures. Cash used in investing activities totaled approximately \$11.0 million during the nine months ended September 30, 2004. The acquisition of Détente and Tempus used cash of approximately \$4.1 million and \$5.1 million, respectively. Capital expenditures used cash of \$3.5 million. These cash outlays were partially offset by a \$1.6 million reduction in a letter of credit which is security for a contract with the State of New Jersey.

Financing activities used cash of \$1.2 million for the three months ended September 30, 2005 primarily due to the payment of \$1.5 million for dividends on the Series A Preferred Stock. For the three months ended September 30, 2004, the repurchase of all of our senior secured notes and our subordinated debentures, together with accrued interest and related redemption premiums used cash of \$62.3 million.

Financing activities used cash of \$3.4 million for the nine months ended September 30, 2005 primarily due to the payment of \$4.2 million for dividends on the Series A Preferred Stock, offset by proceeds from the issuance of common stock as a result of stock option exercises and the \$1.6 million reduction in a standby letter of credit arrangements previously discussed. For the nine months ended September 30, 2004, Series A Preferred Stock was issued, which provided cash of \$96 million offset by \$88 million for the repurchase of all of our senior secured notes and our subordinated debentures, together with accrued interest and related redemption premiums. In addition, \$1.8 million of cash was provided by the issuance of common stock.

At September 30, 2005, the Company's balance of cash and cash equivalents was \$34 million. The Company believes that its current balance of cash and cash equivalents and funds generated from operations, if any, will be sufficient to fund the Company's current projected cash needs for the foreseeable future. The Company may pursue external sources of financing to support additional operational and capital requirements. There can be no assurance that external sources of financing will be available if required, or that such financing will be available on terms acceptable to the Company.

Commitments

The following table summarizes financial data for our contractual obligations and other commercial commitments, including interest obligations, as of September 30, 2005 (in thousands):

	Total	Payments Due by Period			
		Less than 1 year	1-3 years	4-5 years	After 5 years
Contractual Obligations					
Accrued dividends	\$10,312	\$ 5,339	\$ 4,973	\$ —	\$ —
Operating leases (1)	23,031	4,865	13,075	5,091	—
Total contractual obligations	<u>\$33,343</u>	<u>\$10,204</u>	<u>\$18,048</u>	<u>\$5,091</u>	<u>\$ —</u>
Other Commercial Commitments					
Standby letters of credit (2)	\$ 2,393	\$ 2,044	\$ —	\$ —	\$ 349
Total commercial commitments	<u>\$ 2,393</u>	<u>\$ 2,044</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 349</u>

-
- (1) During the fourth quarter of 2004, the Company vacated and closed its San Rafael, California facility as a result of the relocation of our headquarters to Reston, Virginia. The San Rafael lease payments total approximately \$6.2 million for years 2005 through 2009, including the Company's share of common costs. Of this amount, the minimum rent payment of \$4.0 million is included in the schedule above. QuadraMed is actively seeking a tenant for the facility.
 - (2) The less than 1 year figure includes \$1.0 million letter of credit in favor of the State of New Jersey under a customer contract and a \$1.0 million letter of credit relating to a customer agreement.

We believe that we will have sufficient liquidity and capital resources to fund our obligations through the next twelve months.

We expect that cash provided by operating activities may fluctuate in future periods as a result of a number of factors, including fluctuations in our operating results, specifically the timing of when we recognize revenue, our accounts receivable collections and the timing of other payments. In addition, cash used in investing activities may fluctuate due to our software development efforts, any acquisition or disposition we may undertake, and costs associated with our investments in fixed assets and information technology. For additional discussion, see "Business Risks."

Business Risks

We Have Incurred Losses from Continuing Operations for the Past Five Years, Except 2001. Our Losses Have Adversely Affected Our Ability to Compete.

We incurred losses from continuing operations of \$41.8 million, \$23.9 million and \$20.9 million for the years ended December 31, 2004, 2003 and 2002, respectively. Although we had income from continuing operations of \$12.0 million in 2001, we incurred losses from continuing operations of \$39.4 million in 2000. We incurred a loss from continuing operations of \$2.7 million for the nine months ended September 30, 2005.

Our historical losses have impaired our ability to market our products and services in competition against companies that are more profitable. If we are unable to achieve or sustain profitability, it may impair our ability to compete effectively.

We Have Found Material Weaknesses in Our System of Internal Controls over Financial Reporting and Disclosure Controls as of December 31, 2004 and September 30, 2005 that Have Not Been Fully Remediated and that Could Adversely Affect Our Ability to Record, Process, Summarize and Report Certain Financial Data. As a Result, Our Internal Controls over Financial Reporting and Disclosure Controls and Procedures are Ineffective as of December 31, 2004 and September 30, 2005.

In connection with its evaluation of the effectiveness of the Company's internal controls over financial reporting as of December 31, 2004, our management discovered the following control deficiencies in the Company's revenue cycle related to the Company's conversion of its financial records to PeopleSoft:

- The review and supervision of the data entry and contract activation process in connection with the conversion of data for the PeopleSoft modules was inadequate to detect errors in these areas prior to contract activation.
- Not all of our legacy contracts were converted completely into the new PeopleSoft module, requiring the continued need for manual review, impairing management's ability to effectively review, monitor, and investigate movements in customer account balances, and limiting the Company's ability to create meaningful deferred revenue roll forward analysis on a timely basis.

As of September 30, 2005, these control deficiencies have not been remediated. The Company believes that, both individually and in the aggregate, these control deficiencies continued to constitute material weaknesses in

our internal controls over financial reporting as of September 30, 2005, because they resulted in more than a remote likelihood that a material misstatement could occur in our annual or interim financial statements and not be prevented or detected. In fact, these material weaknesses resulted in errors, which were not detected on a timely basis at December 31, 2004 and September 30, 2005. None of these errors, however, resulted in any material adjustments to our financial statements.

Additionally, in February 2004 in connection with its audit of our financial results for 2003, BDO Seidman, LLP (“BDO”) informed our management and Audit Committee of its concern regarding a material weakness in our system of internal controls, policies and procedures to track movements in deferred revenue on a roll forward basis. As a result, it was difficult for management to continually monitor movements in the account. Analytical review was done at the end of each period but not on an overall roll forward basis. While the Company has implemented procedures to report movements in deferred revenue on an overall roll forward basis, the completion of this system was not in place as of December 31, 2004 and September 30, 2005, and therefore, management believes this control deficiency remained a material weakness as of these dates.

The aforementioned weaknesses in our revenue cycle also affected our closing cycle for the fiscal year ended December 31, 2004 and for the fiscal quarters ended March 31, 2005, June 30, 2005, and September 30, 2005. Demands on the time of our staff and their overall workload resulted in inadequate staffing and supervision in our accounting and finance departments, which the Company believes constitutes a significant deficiency in our internal controls as of December 31, 2004 and September 30, 2005, and, in concert with the material weaknesses relating to the revenue cycle discussed above, management has concluded that this deficiency constitutes an additional material weakness in our internal controls over financial reporting as of December 31, 2004 and September 30, 2005.

As a result of these material weaknesses in the Company’s internal controls over financial reporting, management has concluded that as of December 31, 2004 and September 30, 2005, the Company’s internal controls over financial reporting were not effective. Such material weaknesses in internal controls over financial reporting also led our management to conclude that the Company’s disclosure controls and procedures were not effective as of December 31, 2004 and September 30, 2005, to ensure that certain financial information related to these matters required to be disclosed in the Company’s filings and submissions to the SEC under the Securities Exchange Act of 1934 are recorded, processed, summarized and reported within the required time periods.

While management believes that it has taken the appropriate steps to remediate the above material weaknesses by the end of 2005, there can be no assurance that this will occur.

In connection with management’s annual report on internal controls over financial reporting included in the Company’s Form 10-K/A, filed with the SEC on April 29, 2005, the Company’s independent registered public accounting firm, in their report dated April 28, 2005, disclaimed an opinion on management’s assessment and on the effectiveness of our internal control over financial reporting. It is unclear what legal effect the disclaimer of an opinion will have on our compliance with the rules and regulations of the SEC and the continued listing standards of the American Stock Exchange and may adversely affect the trading price of our stock.

Failure to Achieve and Maintain Effective Internal Controls Could Have a Material Adverse Effect on Our Business, Operating Results and Stock Price.

We have documented and tested our internal control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act, which requires annual management assessments of the effectiveness of our internal controls over financial reporting and a report by our independent auditors addressing these assessments. We included these reports in our Amended Annual Report on Form 10-K/A, filed with the SEC on April 29, 2005. As indicated in the previous risk factor, our management has identified control deficiencies and material weaknesses in internal control over financial reporting and in our disclosure controls and procedures. In

addition, if we fail to achieve and maintain the adequacy of our internal controls and disclosure controls, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act. Moreover, effective internal controls, particularly those related to revenue recognition, are important to helping ensure that we produce reliable financial reports and are important to helping prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our stock could drop significantly.

Additional Costs for Complying With Recent and Proposed Future Changes in SEC, American Stock Exchange and Accounting Rules Could Adversely Affect Our Profits.

Recent and proposed future changes in SEC and American Stock Exchange rules, as well as changes in accounting rules, have caused us, and will continue to cause us, to incur additional costs including professional fees and added personnel costs, in order to keep informed of the changes and operate in a compliant manner. We incurred, and expect to continue to incur, additional general and administrative expenses as we implement Section 404 of the Sarbanes-Oxley Act, which requires management to report on, and our independent auditors to attest to, our internal controls. These additional costs may be significant enough to cause our financial position and results of operation to be adversely affected. In addition, compliance with these new rules could also result in continued diversion of management's time and attention, which could prove to be disruptive to our normal business operations. Failure to comply with any of the new laws and regulations could adversely impact market perception of our Company, which could make it difficult to access the capital markets or otherwise finance our operations in the future.

Our Ability to Borrow or Issue Additional Shares of Preferred Stock Is Restricted by the Terms of Our Series A Preferred Stock.

The Certificate of Designation governing our Series A Preferred Stock provides that so long as at least 600,000 shares of Series A Preferred Stock are outstanding, at least 66 $\frac{2}{3}$ % of the votes entitled to be cast by the holders of the Series A Preferred Stock shall be required to approve the incurrence by QuadraMed of any long term, senior indebtedness of QuadraMed in an aggregate principal amount exceeding \$8,000,000, excluding certain prior existing indebtedness. Furthermore, the Certificate of Designation requires the affirmative vote of a majority of any outstanding shares of the Series A Preferred Stock prior to the authorization or creation of, or increase in the authorized amount of, any shares of any class or series (or any security convertible into shares of any class or series) ranking senior to or on par with the Series A Preferred Stock in the distribution of assets upon any liquidation, dissolution or winding up of QuadraMed or in the payment of dividends. This may hinder or delay our ability to borrow funds or issue preferred stock.

We Were Subject to a Formal SEC Inquiry as a Result of the Restatement of Our Financial Statements, and the SEC Has Issued a Cease and Desist Order to which We Have Consented.

Following our August 12, 2002 announcement that we intended to restate prior period financial statements, the staff of the San Francisco District Office of the SEC requested certain information concerning the anticipated restatement as part of an informal, preliminary inquiry.

On February 28, 2003, we reported that the SEC had issued a formal non-public order of investigation concerning our accounting and financial reporting practices for the period beginning January 1, 1998. On October 10, 2003, we announced that the Staff of the San Francisco District Office of the SEC informed us that the Staff intended to recommend to the SEC that it institute an enforcement action against us for violations of the antifraud, periodic filing and books and records provisions of the federal securities laws. The proposed recommendation concerned our accounting for transactions that we entered into with Health+Cast LLP in 1998 and 1999. The 1999 transactions were restated as part of the restatement of our 1999 financial statements. The

individuals who were involved with the Health+Cast transactions are no longer associated with the Company. On April 30, 2004, that matter was settled with the issuance by the SEC of a Cease and Desist Order, to which QuadraMed consented without admitting or denying the findings in the Order. No fine was assessed against QuadraMed in the Order, which requires the Company to cease and desist from violations of the antifraud, periodic reporting and books and records provisions of the Securities Exchange Act of 1934.

The Trading Price of Our Common Stock Has Been, and Is Expected to Continue to Be, Volatile.

The American Stock Exchange and stock markets in general, have historically experienced extreme price and volume fluctuations that have affected companies unrelated to their individual operating performance. The trading price of our common stock has been and is likely to continue to be volatile due to such factors as:

- Variations in quarterly results of operations;
- Announcements of new products or acquisitions by our competitors;
- Government regulatory action;
- Resolution of pending or unasserted litigation;
- Developments or disputes with respect to proprietary rights; and
- General trends in our industry and overall market conditions.

Movements in prices of equity securities in general may also affect the market price of our common stock.

Our Quarterly Operating Results Are Subject to Fluctuations, which Could Adversely Affect Our Financial Results and the Market Price of Our Common Stock.

Our quarterly operating results have varied significantly in the past and may fluctuate in the future as a result of a variety of factors, many of which are outside our control. Accordingly, quarter-to-quarter comparisons of our operating results may not be indicative of our future performance. Some of the factors causing these fluctuations include:

- Variability in demand for products and services;
- Introduction of product enhancements and new products by us and our competitors;
- Timing and significance of announcements concerning present or prospective strategic alliances;
- Discontinuation of, or reduction in, the products and services we offer;
- Loss of customers due to consolidation in the healthcare industry;
- Delays in product delivery requested by our customers;
- Customer budget cycle fluctuation;
- Investment in marketing, sales, software development, and administrative personnel necessary to support anticipated operations;
- Costs incurred for marketing and sales promotional activities;
- Software defects and other product quality factors;
- General economic conditions and their impact on the healthcare industry;
- Cooperation from competitors on interfaces and implementation when a customer chooses a QuadraMed software application to use with various vendors;
- Delays in implementation due to product readiness, customer induced delays in training or installation, and third party interface development delays;

- Final negotiated sales prices of systems;
- Federal regulations (*i.e.*, OIG, HIPAA, ICD-10) that can increase demand for new, updated systems;
- Federal regulations that directly affect reimbursements received, and therefore the amount of money available for purchasing information systems; and
- The fines and penalties a healthcare provider or system may incur due to fraudulent billing practices.

In addition to the foregoing, a significant percentage of our total cost of revenue is attributable to the cost of third party software royalties and licenses relating to third party software embedded within our software applications. The cost of third party software royalties and licenses, as a percentage of total cost of revenue, was approximately 17.6%, 11.0% and 12.7% for the years ended December 31, 2004, 2003, and 2002, respectively. The cost of third party software royalties and licenses, as a percentage of total cost of revenue, was approximately 20.1% and 20.0% for the nine months ended September 30, 2005 and 2004, respectively. Generally, royalty fees for third party licenses will fluctuate based on revenue or the number of our customers and therefore will fluctuate on a quarter to quarter basis.

Our operating expense levels, which increase with the addition of acquired businesses, are relatively fixed. Accordingly, if future revenues are below expectations, we would experience a disproportionate adverse affect on our net income and financial results. In the event of a revenue shortfall, we will likely be unable to, or may elect not to, reduce spending quickly enough to offset any such shortfall. As a result, it is possible that our future revenues or operating results may fall below the expectations of securities analysts and investors. In such a case, the price of our publicly traded securities may be adversely affected.

We Could Experience a Significant Impact on Our Revenue if Our Customers do not Renew Maintenance Contracts.

We derive a significant percentage of our revenue, including 33% of our total revenue for fiscal year 2004, from maintenance services. We provide maintenance services under maintenance contracts to many of our customers in connection with our healthcare information technology products. In general, these maintenance contracts renew on an annual basis. If a significant portion of these maintenance contracts were not renewed, our maintenance revenues would decline which could have a material adverse effect on our total revenue for the period(s) in which the maintenance contracts were discontinued.

Future Sales of Our Common Stock in the Public Market, Warrants or Option Exercises and Sales Could Lower Our Stock Price.

A substantial number of shares of our common stock are subject to stock options and warrants, and are issuable upon conversion of our Series A Preferred Stock. We cannot predict the effect, if any, that future sales of warrants or shares of common stock, or the availability of shares of common stock for future sale, will have on the market price of our common stock. Sales of substantial amounts of common stock, including shares issued upon the exercise of warrants or stock options or the conversion of our Series A Preferred Stock, or the perception that such sales could occur, may adversely affect prevailing market prices for our common stock.

If Our Series A Preferred Stock is Converted into Common Stock, these Converting Stockholders Will Have Significant Voting Power, and They Will Have the Ability to Exert Substantial Influence Over Matters Requiring Stockholder Approval.

Each share of our Series A Preferred Stock is convertible into 8.0645 shares of our common stock, and the Series A Preferred Stockholders may convert at any time. If all of our Series A Preferred Stock is converted into common stock, the shares issued upon this conversion will total approximately 44.3% of our outstanding common stock. In addition, many of our Series A Preferred Stockholders own common stock. Therefore,

although these stockholders may not acquire majority control upon conversion of their Series A Preferred Stock, if these distinct stockholders were to act together, they will have the ability to exert substantial influence over all matters requiring approval of our stockholders, including the election and removal of directors, the approval of mergers or other business combinations, and other significant corporate actions. This ability to influence our affairs might be disadvantageous to our other stockholders.

Recently Adopted Financial Accounting Standards, Which Require the Expensing of All Share-Based Payments to Employees, May Materially and Adversely Affect our Results of Operations.

In December 2004, the Financial Accounting Standards Board (“FASB”) issued SFAS No. 123(R), *Share-Based Payment*, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their grant-date fair values. In April 2005, the SEC extended the effective date of SFAS No. 123(R) requiring compliance by public companies for annual, rather than interim, periods that begin after June 15, 2005. Under SFAS No. 123(R), pro forma disclosure is no longer an alternative. As permitted by the former FASB statement, SFAS No. 123, the Company currently accounts for share-based payments to employees using the intrinsic value method under Accounting Principles Board (“APB”) Opinion No. 25, “Accounting for Stock Issued to Employees”, and as such, generally recognizes no compensation cost for employee stock options. Accordingly, the adoption of SFAS No. 123(R)’s fair value method may have a significant impact on the Company’s results of operations as we will be required to recognize the cost of employee services received in exchange for awards of equity instruments based on the grant-date fair value of those awards. The impact of adoption of SFAS No. 123(R) cannot be predicted at this time because it will depend on levels of share-based payments granted in the future, and the Company is currently evaluating the impact SFAS No. 123(R) will have on its financial statements. However, expensing employee stock options and restricted stock pursuant to SFAS No. 123(R) may adversely affect our operating results as these awards would be charged against our reported earnings. If the Company reduced its share-based payments to existing and new employees in order to avoid the negative impact on operating results, it could impair the Company’s ability to attract and retain quality personnel, which could weaken the Company’s competitive position in the marketplace.

Provisions in Our Certificate of Incorporation and Bylaws and Delaware Law Could Delay or Discourage a Takeover which Could Adversely Affect the Price of Our Common Stock.

Our Board of Directors has the authority to issue an additional one million shares of preferred stock over and above the four million shares already issued, and to determine the price, rights, preferences, privileges, and restrictions, including voting rights, of those shares without any further vote or action by holders of our common stock. If additional preferred stock is issued, the voting and other rights of the holders of our common stock may be subject to, and may be adversely affected by, the rights of the holders of our preferred stock. The issuance of preferred stock may have the effect of delaying or preventing a change of control of the Company that could have been at a premium price to our stockholders. Our Board of Directors has issued four million shares of such preferred stock as Series A Preferred Stock and the holders of the Series A Preferred Stock have certain voting and board appointment rights.

Certain provisions of our Certificate of Incorporation and Bylaws could discourage potential takeover attempts and make attempts to change management by stockholders difficult. Our Board of Directors has the authority to impose various procedural and other requirements that could make it more difficult for our stockholders to effect certain corporate actions. In addition, our Certificate of Incorporation provides that directors may be removed only by the affirmative vote of the holders of two-thirds of the shares of our capital stock entitled to vote. Any vacancy on our Board of Directors may be filled only by a vote of the majority of directors then in office. Further, our Certificate of Incorporation provides that the affirmative vote of two-thirds of the shares entitled to vote, voting together as a single class, subject to certain exceptions, is required for certain business combination transactions. These provisions, and certain other provisions of our Certificate of Incorporation, could have the effect of delaying or preventing (i) a tender offer for our common stock or other changes of control of the Company that could be at a premium price or (ii) changes in our management.

In addition, certain provisions of Delaware law could have the effect of delaying or preventing a change of control of the Company. Section 203 of the Delaware General Corporation Law, for example, prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years from the date the person became an interested stockholder unless certain conditions are met.

We Do Not Expect to Pay Cash Dividends on Common Stock in the Foreseeable Future.

We have not declared or paid cash or other dividends on our common stock and do not expect to pay cash dividends for the foreseeable future. Our ability to pay dividends is also restricted by the terms of our Series A Preferred Stock which require us to pay full cumulative dividends on the Series A Preferred Stock before making any dividend payment on our common stock. Generally, the Series A Preferred Stock is entitled to quarterly dividends of \$0.34 (5.5% per annum) per share. However, as provided in the Certificate of Designation relating to the Series A Preferred Stock, because a registration statement covering resales of the Series A Preferred Stock and the common stock into which the Series A Preferred Stock is convertible, was not declared effective by the SEC on or before June 15, 2005, the dividend rate for such stock has increased to \$0.40625 per quarter (\$1.625 per annum) commencing on June 16, 2005, and such rate will apply until the date the registration statement is declared effective. Upon conversion of the Series A Preferred Stock into shares of common stock, the Series A Preferred stockholders have the right to receive, when declared by our Board of Directors, dividends equal to the total previously unpaid dividends payable from the effective date of conversion through June 1, 2007 at a rate of \$1.375 per share per annum or 5.5% per annum, discounted to present value at a rate of 5.5% per annum, payable in cash or common shares, or any combination thereof at our option. We currently intend to retain all future earnings for use in the operation of our business and to fund future growth. Any future cash dividends will depend upon our results of operations, financial conditions, cash requirements, the availability of a surplus and other factors.

We May Be Liable for Violating the Intellectual Property Rights of Third Parties, which Could Lead Us to Incur Substantial Litigation Expenses, and, If There Were an Adverse Judgment, Liability for Any Infringement.

We do not believe that the intellectual property important to the operation of our business, whether owned by us or licensed to us by a third party, infringes or violates the intellectual property rights of any other party. However, intellectual property litigation is increasingly common in the software industry. The risk of an infringement claim against us may increase over time as the number of competitors in our industry segment grows and the functionality of products overlaps. Third parties have, in the past, asserted infringement claims and could assert infringement claims against us in the future. Regardless of the merits, we could incur substantial litigation expenses in defending any such asserted claim. In the event of an unfavorable ruling on any such claim, a license or similar agreement may not be available to us on reasonable terms, if at all. Infringement may also result in significant monetary liabilities that could have a material adverse effect on our business, financial condition, and results of operations. We may not be successful in the defense of these or similar claims. We have taken steps to contractually limit our liability for the use of intellectual property licensed to us by third parties. However, there can be no guarantee that we have adequate protection.

Our Inability to Protect Our Intellectual Property Could Lead to Unauthorized Use of Our Products, which Could Have an Adverse Effect on Our Business.

We rely on a combination of trade secret, copyright and trademark laws, nondisclosure, non-compete, and other contractual provisions to protect our proprietary rights. In 2001, we filed our first patent application covering our developed technology, the Affinity CPOE software application. This application lapsed, and we have no patents. Measures taken by us to protect our intellectual property may not be adequate, and our competitors could independently develop products and services that are substantially equivalent or superior to our products and services. Any infringement or misappropriation of our proprietary software and databases could put us at a competitive disadvantage in a highly competitive market and could cause us to lose revenues, incur substantial litigation expense, and divert management's attention from other operations.

We are Dependent Upon Third Party Software Licenses in Connection with the Sale of Our Software. If These Licenses Are Not Renewed or Are Terminated, We May Not Be Able to Continue to Use the Related Technology on Commercially Reasonable Terms or at All.

We depend on licenses from a number of third party vendors for certain technology, including the computer hardware, operating systems, database management systems, programming language, and runtime environment, upon which we develop and operate our products. We are materially reliant upon licenses with the following third party vendors: InterSystems Corporation, Document Storage Systems, Inc., Megas Corporation, Unicor Medical, Oracle, Microsoft, Quovadx, the American Medical Association (AMA), and the American Hospital Association (AHA). Most of these licenses expire within three to five years. Such licenses can be renewed only by mutual consent and may be terminated if we breach the license terms and fail to cure the breach within a specified time period. If such licenses are terminated, we may not be able to continue using the technology on commercially reasonable terms or at all. As a result, we may have to discontinue, delay or reduce product shipments until equivalent technology is obtained, which could have a material adverse effect on our business, financial condition, and results of operations. However, as all application software companies, including QuadraMed and our competitors, are reliant on licensed technology and third party components, we believe our reliance on such technology and licenses places us at no competitive disadvantage.

At present, there is no equivalent technology for the InterSystems Corporation technology which is an integral component of our Affinity product line. The Company has entered into several agreements with InterSystems Corporation regarding the licensed technology relating to our Affinity product line. However, if InterSystems Corporation ceased to offer this technology and no other vendor provided the technology, we would be required to migrate our Affinity products to a new database platform or redesign our products to work with new software tools. This could be very costly and difficult to achieve and could have a material adverse effect on our business, financial condition and results of operations. There can be no assurance that we would successfully migrate our Affinity products to a new platform. Most of our third party licenses are non-exclusive and competitors may obtain the same or similar technology. In addition, if vendors choose to discontinue support of the licensed technology, we may not be able to modify or adapt our products.

We Face Product Development Risks Associated with Rapid Technological Changes.

The healthcare software market is highly fragmented and characterized by ongoing technological developments, evolving industry standards, and rapid changes in customer requirements. Our success depends on our ability to timely and effectively:

- Offer a broad range of software products;
- Enhance existing products and expand product offerings;
- Respond promptly to new customer requirements and industry standards;
- Remain compatible with popular operating systems and develop products that are compatible with the new or otherwise emerging operating systems; and
- Develop new interfaces with competing HIS vendors to fully integrate our Quantim product suite in order to maximize features and functionality of the new products.

Our performance depends in large part upon our ability to provide the increasing functionality required by our customers through the timely development and successful introduction of new products and enhancements to our existing suite of products. We may not successfully, or in a timely manner, develop, acquire, integrate, introduce, or market new products or product enhancements. Product enhancements or new products developed by us also may not meet the requirements of hospitals or other healthcare providers and payers or achieve or sustain market acceptance. Our failure to either estimate accurately the resources and related expenses required for a project, or to complete our contractual obligations in a manner consistent with the project plan upon which a contract was based, could have a material adverse effect on our business, financial condition, and results of operations. In addition, our failure to meet a customer's expectations in the performance of our services could damage our reputation and adversely affect our ability to attract new business.

A Significant Amount of Our Assets Comprise Goodwill, Customer Lists and Other Intangible Items Subject to Impairment and Adjustment That Could Possibly Negatively Impact Our Results of Operations and Stockholders' Equity.

A significant amount of our assets comprise intangible assets, such as the value of the installed customer base, core technology, capitalized software, goodwill, and other identifiable intangible assets acquired through our acquisitions, such as trademarks.

Pursuant to SFAS No. 142, we must test goodwill and other intangible assets for impairment at least annually and adjust them when impaired to the appropriate net realizable value. We performed an impairment test on the carrying value of our goodwill and intangibles as of January 1, 2005 and 2004. We determined that there was no impairment as of these dates. In addition, our internally developed software has been capitalized assuming our earnings from these product developments exceeds the costs incurred to develop them. If it is determined that these assets have been impaired and our future operating results will not support the existing carrying value of our intangible assets, we will be required to adjust the carrying value of such assets to net realizable value.

We, however, cannot predict that all of our intangible assets will continue to remain unimpaired. Our future operating results and stockholders' equity could possibly decrease with any future impairment and write-down of goodwill, customer lists, or other such intangibles.

The Nature of Our Products Makes Us Particularly Vulnerable to Undetected Errors or Bugs that Could Reduce Revenues, Market Share or Demand for Our Products and Services.

Products such as those we offer may contain errors or failures, especially when initially introduced or when new versions are released. Although we conduct extensive testing on our products, software errors have been discovered in certain enhancements and products after their introduction. Despite such testing by us and by our current and potential customers, products under development, enhancements, or shipped products may contain errors or performance failures, resulting in, among other things:

- Loss of customers and revenue;
- Delay in market acceptance;
- Diversion of resources;
- Damage to our reputation; or
- Increased service and warranty costs.

Any of these consequences could have a material adverse effect on our business, financial condition, and results of operations.

If Our Products Fail to Accurately Assess, Process, or Collect Healthcare Claims or Administer Managed Care Contracts, We Could Be Subject to Costly Litigation and Be Forced to Make Costly Changes to Our Products.

Some of our products and services are used in the payment, collection, coding, and billing of healthcare claims and the administration of managed care contracts. If our employees or products fail to accurately assess, process, or collect these claims, customers could file claims against us. Our insurance coverage may not be adequate to cover such claims. A successful claim that is in excess of, or is not covered by, insurance coverage could adversely affect our business, financial condition, and results of operations. Even a claim without merit could result in significant legal defense costs and could consume management time and resources. In addition, claims could increase our premiums such that appropriate insurance could not be found at commercially reasonable rates. Furthermore, if we were found liable, we may have to significantly alter one or more of our products, possibly resulting in additional unanticipated software development expenses.

Changes in Procurement Practices of Hospitals Have and May Continue to Have a Negative Impact on Our Revenues.

A substantial portion of our revenues has been and is expected to continue to be derived from sales of software products and services to hospitals. Hospitals are slow to make changes and generally favor their existing vendor when considering an upgrade in their systems. Consolidation in the healthcare industry, particularly in the hospital and managed care markets, could decrease the number of existing or potential purchasers of products and services and could adversely affect our business. In addition, the decision to purchase our products often involves a committee approval. Consequently, it is difficult for us to predict the timing or outcome of the buying decisions of our customers or potential customers. In addition, many healthcare providers are consolidating to create integrated delivery networks with greater regional market power. These emerging systems could have greater bargaining power, which may lead to decreases in prices for our products, which could adversely affect our business, financial condition, and results of operations.

The Department of Veterans Affairs Has Awarded a Contract to Us. It is Unknown Whether Our Overall Revenues Will Increase or Not Related to This Award.

The Department of Veterans Affairs (“VA”) has awarded contract VA Blanket Purchase Agreement No. 101-049AH-005 (the “BPA”) to the Company, as disclosed in the Company’s press release dated April 27, 2005. The BPA is a five-year single source contract covering approximately 128 VA facilities. Under the BPA, these VA facilities are to be contracted to use our products and services. Previously, both we and other vendors have provided HIM software to these VA facilities. As of December 31, 2004, we had approximately \$12.9 million in annual revenue from providing VA facilities with software. The BPA contains additional HIM software discounts, but it increases the number of VA facilities using our products, so the overall financial impact of the BPA cannot be known. Additionally, the VA is directing the individual facilities to order their requirements for this HIM software under the BPA, but each VA facility orders the HIM software individually, and there can be no guarantee that a VA facility will order its HIM software and/or services from us. For these reasons there can be no assurances what, if any, material financial impact the BPA will have.

Changes in the Healthcare Financing and Reimbursement System Could Adversely Affect the Amount of and Manner in which Our Customers Purchase Our Products And Services.

Changes in current healthcare financing and reimbursement systems (e.g. Medicaid) could result in unplanned product enhancements, delays, or cancellations of product orders or shipments, or reduce the need for certain systems. We could also have the endorsement of products by hospital associations or other customers revoked. Any of these occurrences could have a material adverse effect on our business. Alternatively, the federal government recently mandated that all but small healthcare providers submit claims to Medicare in electronic format, which may positively affect our systems and product.

The healthcare industry in the United States is subject to changing political, economic, and regulatory influences that may affect the procurement practices and operations of healthcare organizations. The traditional hospital delivery system is evolving as more hospital services are being provided by niche, free standing practices and outpatient providers. The commercial value and appeal of our products may be adversely affected if the current healthcare financing and reimbursement systems were to change. During the past several years, the healthcare industry has been subject to increasing levels of governmental regulation. Proposals to reform the healthcare system have been and are being considered by the United States Congress. These proposals, if enacted, could adversely affect the commercial value and appeal of our products or change the operating environment of our customers in ways that cannot be predicted. Healthcare organizations may react to these proposals by curtailing or deferring investments, including those for our products and services. In addition, the regulations promulgated under the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) could lead healthcare organizations to curtail or defer investments in non-HIPAA related features in the next several years.

The Variability and Length of Our Sales Cycle for Our Products May Exacerbate the Unpredictability and Volatility of Our Operating Results.

We cannot accurately forecast the timing of customer purchases due to the complex procurement decision processes of most healthcare providers and payers. How and when to implement, replace, expand or substantially modify an information system are major decisions for hospitals, and such decisions require significant capital expenditures by them. As a result, we typically experience sales cycles that extend over several quarters. In particular, our Affinity enterprise software has a higher average selling price and longer sales cycle than many of our other products. As a result, we have only a limited ability to forecast the timing and size of specific sales, making the prediction of quarterly financial performance more difficult.

We Operate in a Highly Competitive Market.

Competition for our products and services is intense and is expected to increase. Increased competition could result in reductions in our prices, gross margins, and market share and have a material adverse effect on our business, financial condition, and results of operations. We compete with other providers of healthcare information software and services, as well as healthcare consulting firms. Some competitors have formed business alliances with other competitors that may affect our ability to work with some potential customers. In addition, if some of our competitors merge, a stronger competitor may emerge. Some principal competitors include:

- In the market for enterprise healthcare information systems: McKesson Corporation, Inc., Shared Medical Systems, Inc., a division of Siemens, MediTech Corporation, Eclipsys Corporation, Cerner, and IDX Corporation;
- In the market for electronic document management products: McKesson Corporation, SoftMed Corporation Inc., FileNet, LanVision, MedPlus, and Eclipsys Corporation;
- In the market for MPI products and services: Madison, McKesson Corporation, Shared Medical Systems, Inc., a division of Siemens, and Medibase;
- In the market for decision support products: Eclipsys Corporation, Healthcare Microsystems, Inc., a division of Health Management Systems Inc., McKesson Corporation, Shared Medical Systems, Inc., a division of Siemens, and MediQual Systems, Inc., a division of Cardinal Health, Inc.;
- In the market for coding, compliance, data, and record management products in the Health Information Management Software Division: 3M Corporation, SoftMed Corporation, Inc., MetaHealth, Eclipsys Corporation and HSS, Inc.;

Prospective customers may evaluate our products' capabilities against the merits of their existing information systems and expertise and may decide to stay with their incumbent vendor because of the cost associated with conversion. In addition, exiting and prospective customers may be reluctant to buy from us because of the losses we have incurred in recent years.

Many of our competitors and potential competitors have significantly greater financial, technical, product development, marketing and other resources, and market recognition than we have. These competitors may be in a position to devote greater resources to the development, promotion, and sale of their products than we can. Our competitors also have, or may develop or acquire, substantial installed customer bases in the healthcare industry. As a result of these factors, our competitors may be able to respond more quickly to new or emerging technologies, changes in customer requirements, and changes in the political, economic or regulatory environment in the healthcare industry.

As a result of the current emphasis on patient safety, the selection of a new Hospital Information System is frequently based on the strength of the vendor's clinical application and many of our competitors have invested considerably more in clinical development than we have.

Major software information systems companies, including those specializing in the healthcare industry, that do not presently offer competing products may enter our markets.

We may not be able to compete successfully against current and future competitors, and such competitive pressures could materially adversely affect our business, financial condition, and operating results.

We Have Encountered Significant Challenges Integrating Acquired Businesses, and Future Transactions May Adversely Affect Our Business, Operations, and Financial Condition.

Throughout our history, we have made many acquisitions, and we encountered significant challenges integrating the acquired businesses into our operations. In recent years, we have made significant progress toward that integration. However, we continue to support several different technology platforms. In February 2004, we acquired Détente Systems Pty Limited, an Australian proprietary limited company, and Détente Systems Trust, an Australian business trust, and in June 2004, we acquired Tempus Software, Inc., a Florida corporation. In the future, we plan to make investments in or acquire additional complementary businesses, products, services or technologies. These investments and acquisitions will create new integration challenges. Some of the challenges we have encountered, and may encounter with acquisitions in the future, in integrating acquired businesses have included:

- Interruption, disruption or delay of our ongoing business;
- Distraction of management's attention from other matters;
- Additional operational and administrative expenses;
- Difficulty managing geographically dispersed operations;
- Failure of acquired businesses to achieve expected results, resulting in our failure to realize anticipated benefits;
- Write-down or reclassification of acquired assets;
- Failure to retain key acquired personnel and difficulty and expense of training those retained;
- Increases in stock compensation expense and increased compensation expense resulting from newly hired employees;
- Assumption of liabilities and potential for disputes with the sellers of acquired businesses;
- Customer dissatisfaction or performance problems related to acquired businesses;
- Failure to maintain good relations with customers or suppliers;
- Exposure to the risks of entering markets in which we have no direct prior experience and to risks associated with market acceptance of acquired products and technologies; and
- Platform and technical issues related to integrating systems from various acquired companies.

All of these factors have had an adverse effect on our business, financial condition, and results of operations in the past, and could have an adverse effect in the future.

No Mirror Processing Site for Our Customer Data Processing Facilities Exists; Our Business, Financial Condition, and Results of Operations Could Be Adversely Affected if These Facilities Were Subject to a Closure from a Catastrophic Event or Otherwise.

We currently process substantially all of our customer data at several of our facilities across the United States. Although we back up our data nightly and have safeguards for emergencies, such as power interruption or breakdown in temperature controls, we have no mirror processing site to which processing could be transferred in the case of a catastrophic event at any of these facilities. If a major catastrophic event occurs at these facilities possibly leading to an interruption of data processing, or any other interruption or closure, our business, financial condition, and results of operations could be adversely affected.

We May Be Required to Make Substantial Changes to Our Products if They Become Subject to FDA Regulation, which Could Require a Significant Capital Investment.

Computer products used or intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases or other conditions or that affect the structure or function of the body are subject to regulation by the FDA under the Federal Food, Drug and Cosmetic Act. At present, none of our software products are so regulated. In the future, the FDA could determine that some of our products, because of their predictive aspects, are clinical decision tools and subject them to regulation. Compliance with FDA regulations could be burdensome, time consuming, and expensive. Other new laws and regulations affecting healthcare software development and marketing also could be enacted in the future. If so, it is possible that our costs and the length of time for product development and marketing could increase and that other unforeseeable consequences could arise.

Governmental Regulation of the Confidentiality of Patient Health Information Could Result in Our Customers Being Unable to Use Our Products Without Significant Modification, which Could Require Us to Expend Substantial Amounts.

There is substantial state and federal regulation of the confidentiality of patient health information and the circumstances under which such information may be used by, disclosed to, or processed by us as a consequence of our contacts with various health plans and healthcare providers. Although compliance with these laws and regulations is presently the principal responsibility of the health plan, hospital, physician, or other healthcare provider, regulations governing patient confidentiality rights are dynamic and rapidly evolving. As such, laws and regulations could be modified so that they could directly apply to us. Also, changes to the laws and regulations that would require us to change our systems and our methods may be made in the future, which could require significant expenditure of capital and decrease future business prospects. Also, additional federal and state legislation governing the dissemination of patient health information may be proposed and may be adopted, which may also significantly affect our business. Finally, certain existing laws and regulations require healthcare entities to pass-on their obligations to other entities with which they do business, through a contract; as such, we are indirectly impacted by various additional laws and regulations.

The Health Insurance Portability and Accountability Act of 1996 is a federal law that affects the use, disclosure, transmission and storage of individually identifiable health information referred to as protected health information. As directed by HIPAA, the United States Department of Health and Human Services (“HHS”) must promulgate standards or rules for certain electronic health transactions, code sets, data security, unique identification numbers, and privacy of protected health information. HHS has issued some of these rules in final form, while others remain in development. In general, under these rules, we function as a “business associate” to some of our customers (who are considered to be “covered entities” under HIPAA). The three rules relevant to us and our customers—the Transaction Rule, the Privacy Rule, and the Security Rule—are discussed below. It is important to note that HHS could, at any time in the future, modify any existing final rule in a manner that could require us to change our systems or operations.

First, HHS has published a final rule governing transactions and code set standards (“Transactions Rule”). The Transactions Rule had a compliance date of October 16, 2003. To the extent necessary to help our covered entity customers conduct transactions, our current products and services meet the requirements of the Transactions Rule. Nevertheless, as noted above, HHS may make further revisions to the Transactions Rule, which could require us to change our products and systems to enable our covered entity customers to meet such obligations.

Second, HHS has published a final HIPAA privacy rule (“Privacy Rule”) which had a compliance date of April 14, 2003. The Privacy Rule is complex and far reaching. Similar to the Transactions Rule, and as noted above, the Privacy Rule directly applies to covered entities. Also, covered entities are, in most instances, required to execute a contract with any business associate that performs certain services on the covered entity’s behalf involving the exchange or creation of protected health information. Our hospital and health plan customers are covered entities, and to the extent that we are required by our customer contracts to ensure that we comply with various aspects of the Privacy Rule, we meet the requirements of the Privacy Rule. The Privacy Rule and other similar state healthcare privacy regulations could materially restrict the ability of healthcare providers and health

plans to disclose protected health information from patient records using our products and services, or it could require us to make additional capital expenditures to be in compliance. Accordingly, the Privacy Rule and state privacy laws may significantly impact our product's use in the healthcare delivery system and, therefore, decrease our revenue, increase working capital requirements and decrease future business prospects.

Third, HHS has published the final HIPAA security rule ("Security Rule") with a compliance date of April 20, 2005. The Security Rule applies to the use, disclosure, transmission, storage and destruction of electronic protected health information by covered entities. Per the Security Rule, covered entities must implement administrative, technical and physical security measures to safeguard electronic protected health information. Also, as with the Privacy Rule, under the Security Rule, covered entities are required to contractually bind their business associates to certain aspects of the Security Rule. As such, where we function as a business associate to a customer that is a covered entity, we are required to enter into a business associate contract with that customer. Implementing such measures may require us to expend substantial capital due to required product, service, and procedure changes.

We have completed modifications to our business practices and software offerings so that we are able to assist our customers in complying with the Transaction Rule, Privacy Rule, and Security Rule. However, HHS continues to publish change notices to the existing rules and propose new rules. There is no certainty that we will be able to respond to all such rules in a timely manner and our inability to do so could adversely affect our business.

Government Regulation to Adopt and Implement ICD-10-CM and ICD-10-PCS Medical Code Set Standards Could Require Substantial Modification of our Coding and Compliance Software.

The American Health Information Management Association and other prominent healthcare industry advocacy groups are calling on HHS and the healthcare industry to take action to adopt and implement ICD-10-CM and ICD-10-PCS code sets, rules, and guidelines as a replacement for current ICD-9-CM guidelines used in our software products. Adoption of these new code sets would require us to change our systems and our methods which could require a significant expenditure of software development capital and decrease future business prospects for our current product line.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

In addition to the market risks discussed herein, refer to our discussion of business risks in *Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations*, above.

Interest Rate Risk

Our exposure to market risk for changes in interest rates primarily relates to our investment portfolio. It is our intent to ensure the safety and preservation of our invested principal funds by limiting default risk, market risk, and reinvestment risk. We invest in high-quality issuers, including money market funds, corporate debt securities, and debt securities issued by the U. S. government and U.S. governmental agencies. We have a policy of investing in securities with maturities of two years or less. We do not invest in derivative financial or foreign investments.

The table below presents fair values of principal amounts and weighted average interest rates for our investment portfolio as of September 30, 2005 (in thousands, except average interest rates):

	<u>Aggregate Fair Value</u>	<u>Weighted Average Interest Rate</u>
Cash and Cash equivalents:		
Cash	\$18,375	
Money Market funds	15,617	3.07%
Total cash and Cash equivalents(1)	<u>\$33,992</u>	
Long-term investments:		
Corporate debt securities	\$ 544	4.93%
Debt issued by US government	812	5.03%
Total long-term investments	<u>\$ 1,356</u>	

(1) Excluded from the fair value of the principal amounts of cash is \$2.4 million, which is restricted cash that is held in escrow for rental properties, and meeting customer performance expectations.

Performance of Equity Markets

The performance of the equity markets can have an effect on our operations as certain of our variable life insurance policies have premiums invested in equity securities.

Foreign Currency Risk

Our primary market risk exposure relates to changes in foreign currency exchange rates and potentially adverse effects of differing tax structures. Changes in foreign exchange rates did not materially impact our results of operations. For the nine months ended September 30, 2005, less than 3% of total revenue was denominated in currencies other than the U. S. dollar and less than 3% of our total direct and operating costs were incurred in currencies other than the U. S. dollar.

Item 4. Controls and Procedures

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

In connection with the preparation of our Annual Report on Form 10-K for the fiscal year ended December 31, 2004, our management, in consultation with the Audit Committee of the Board of Directors, identified material weaknesses, as described below.

Revenue Cycle

In the fourth quarter of 2004, the Company began the process of converting a significant portion of its financial records (principally revenue cycle related items) from a legacy system called “CDI”, to various modules of our principal financial software, PeopleSoft. As of September 30, 2005, this conversion to PeopleSoft is substantially complete.

PeopleSoft is a widely used and very powerful software system. While we have encountered no significant difficulties in expanding the use of the various PeopleSoft modules, planning for the conversion was flawed in that our estimate of the time and resources required to successfully complete the process was underestimated. In addition, the training of personnel in the contract data entry process was inadequate to ensure the accurate entry of data into the system.

As a result, management has concluded that the following control deficiencies in our revenue cycle existed as of December 31, 2004 and continued to exist as of September 30, 2005:

- The training of contract accounting staff and the review and supervision of the data entry and contract activation process in connection with the data conversion, including access controls to the PeopleSoft contracts module, was inadequate to detect errors before contract activation.
- Not all of the legacy contracts were converted completely into the new PeopleSoft module, resulting in the need to continue the use of manual processes, which significantly impairs management's ability to effectively review, monitor and investigate movements in customer account balances. It also limits our ability to create meaningful deferred revenue roll forward analysis on a timely basis.

As of September 30, 2005, these control deficiencies have not been remediated. The Company believes that, both individually and in the aggregate, these control deficiencies continued to constitute material weaknesses in our internal controls over financial reporting as of September 30, 2005, because they resulted in more than a remote likelihood that a material misstatement could occur in our annual or interim financial statements and not be prevented or detected. In fact, these material weaknesses resulted in errors, which were not detected on a timely basis. None of these errors, however, resulted in any material adjustments to our financial statements.

In addition to the material weaknesses described above, in connection with performing its audit of our financial results for 2003, BDO Seidman, LLP ("BDO") informed us that they noted a matter involving internal control that they considered to be a material weakness. The material weakness noted by BDO concerned the fact that the Company had not implemented procedures to track movements in deferred revenue on an overall roll forward basis. As a result, it was difficult for management to continually monitor movements in the account. Analytical review was done at the end of each period but not on an overall roll forward basis. While the Company has implemented procedures in the legacy systems to report movements in deferred revenue on an overall roll forward basis, the completion of this in PeopleSoft was not in place as of September 30, 2005. Accordingly, as of September 30, 2005, management believes that this control deficiency remained a material weakness.

The Company continues to invest significant effort and resources to eliminate these deficiencies in internal controls, and will continue to do so throughout 2005. We will not, however, be in a position to change our current assessment of internal controls until we perform a comprehensive assessment of such controls as part of our 2005 Sarbanes-Oxley Section 404 procedures by December 31, 2005.

Closing Cycle

The aforementioned weaknesses in our revenue cycle also affected our closing cycle for the fiscal year ended December 31, 2004 and for the fiscal quarters ended March 31, June 30, and September 30, 2005. The manual processes referred to above were performed substantially by our accounting and finance staff, with some reliance on outside consultants, who are the same individuals who are involved in the normal closing cycle. As a result, our quarterly close processes were affected in that less time was available from our staff for normal closing and review procedures, and these procedures are an important component of our controls surrounding the closing process. This situation was exacerbated by the fact that we replaced our corporate controller on January 11, 2005. We believe that these demands on the time of our staff and their overall workload resulted in inadequate staffing and supervision in our accounting and finance departments, which the Company believes continued to constitute a significant deficiency in our internal controls as of September 30, 2005 and, taken together with the material weaknesses relating to the revenue cycle discussed above, remained an additional material weakness in our internal controls over financial reporting as of September 30, 2005.

Through the third fiscal quarter of 2005, we have taken steps to bolster the personnel involved in the closing cycle and have initiated what we believe to be improved processes and a better delineation of duties. While there can be no assurance in this regard, we expect that these steps will eliminate this material weakness in 2005. Until that time, we will continue to rely on manual processes and require additional commitment of resources to the closing process to produce our financial records and reports.

As a result of the material weaknesses relating to our revenue cycle and our closing cycle noted above, management has concluded that as of September 30, 2005, the Company did not maintain effective internal control over financial reporting.

Other than the actions mentioned above, there has been no change to the Company's internal control over financial reporting that occurred during the quarter ended September 30, 2005 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

The Company has hired an outside consulting firm to assist:

- in assessing the control environment in our transaction cycles,
- in preparing 2005 control documentation,
- in performing cycle risk assessment,
- in identifying and remediating control deficiencies, and
- in designing and performing control testing in these cycles.

While management believes that it has taken the appropriate steps to remediate the above material weaknesses by the end of 2005, there can be no assurance that this will occur.

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

We have established disclosure controls and procedures to ensure that material information relating to the Company is made known to the officers who certify the financial statements and to other members of senior management and the Audit Committee of the Board of Directors. As of September 30, 2005, an evaluation was performed under the supervision and with the participation of the Company's management, including the Chief Executive Officer (the "CEO") and the Chief Financial Officer (the "CFO"), of the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e), and 15d-15(e) under the Securities Exchange Act of 1934). Based on the material weaknesses in internal controls over financial reporting discussed above, the Company's management, including the CEO and CFO, concluded that the Company's disclosure controls and procedures were not effective as of the end of the period covered by this report.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

In January 2004, Mr. James Durham, the Company's former Chief Executive Officer, filed an amended complaint against us in the Superior Court of the State of California, Marin County, alleging a breach of his SERP contract and a breach of good faith and fair dealing under this contract. This amended complaint seeks payment of his lump sum SERP benefits, interest, attorneys' fees, and other relief. On January 30, 2004, this matter was moved to the United States District Court, Northern District of California. On May 6, 2005, the Court, over our objection, entered judgment in favor of Mr. Durham against us, in the total amount of \$5,067,130, plus interest thereon, at the rate prescribed by 28 U.S.C. §1961 accruing after that date. On July 6, 2005, the Company settled its litigation with Mr. James Durham. Under the terms of the Settlement Agreement and General Release ("Settlement Agreement") between the parties, the Company made an immediate cash payment of approximately \$3.6 million to Mr. Durham and issued a Negotiable Promissory Note (the "Note") to Mr. Durham in the principal amount of \$1.4 million and with an interest rate of 5.12% per annum. As of June 30, 2005, the Company has fully accrued for the payment. The timing of payments under the Note is linked to the Company's realization of amounts invested in a split-dollar insurance arrangement (the "Split-Dollar Policy") with Mr. Durham. The immediate payment of \$3.6 million was funded principally by the liquidation of certain assets earmarked for such purpose, in the amount of \$3.1 million, and payment of \$0.5 million out of operating cash. The Company's obligations under the Note are secured by a collateral assignment of the Company's rights under the Split-Dollar Policy and certain related agreements. The Settlement Agreement includes various releases from both parties.

On November 15, 2004, the Company received a letter from MedCath Incorporated ("MedCath"), which provided notice of MedCath's decision to terminate the Master Software License and Services Agreement, dated November 20, 2002, by and between QuadraMed Affinity and MedCath (the "Contract"). On or about November 15, 2004, MedCath filed a complaint against us in the North Carolina Superior Court, County of Mecklenburg. In its complaint, MedCath alleges that we are in breach of the Contract due to uncured deficiencies in the products, and seeks at least \$5 million in damages, plus litigation costs. We believe that these allegations are without merit and that the termination of the Contract is unwarranted. On December 9, 2004, we filed a motion to dismiss the MedCath complaint on the grounds that the complaint fails to state a claim upon which relief can be granted. We also filed a counterclaim against MedCath seeking no less than \$1.14 million in unpaid amounts due to us, plus litigation costs, for MedCath's breach of the Contract by failing to pay licensing fees due to the Company. A case management conference was held July 29, 2005 in the Superior Court before a judge to whom the case has been assigned. On August 15, 2005, the Court issued a case management order which, among other things, provides for all fact discovery to be completed by April 15, 2006, provides for all expert discovery to be completed by July 15, 2006, and provides for the parties to submit the dispute to mediation on or before April 30, 2006. On October 19, 2005, the Court issued an order denying our motion to dismiss. We will continue to defend ourselves vigorously against any claim that we have breached the Contract and will seek redress through all applicable remedies for any injuries suffered by the Company in connection with this matter.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On August 1, 2005, we issued 100,000 restricted shares of our common stock to James R. Klein, our Chief Technology Officer, and on October 17, 2005, we issued 550,000 restricted shares of our common stock to Keith B. Hagen, our Chief Executive Officer, in each case as an inducement to their employment by the Company. These shares of restricted stock are subject to contractual limitations, including provisions regarding forfeiture and disposition. The forfeiture restrictions on Mr. Klein's shares of restricted stock lapse (i) 35,000 shares on August 1, 2006, 35,000 shares on August 1, 2007, and 30,000 shares on August 1, 2008, if Mr. Klein has been employed continuously by the Company on each date; or (ii) immediately for all 100,000 shares upon Mr. Klein's termination by Involuntary Termination or Change in Control (as such terms are defined in Mr. Klein's Restricted Stock Agreement with the Company). The forfeiture restrictions on Mr. Hagen's shares of restricted stock lapse on October 17, 2008 if Mr. Hagen has been continuously employed by the Company on that

date or immediately for all 550,000 shares upon an Involuntary Termination (other than a Termination for Cause) of Mr. Hagen's employment or upon a Change in Control (as such terms are defined in Mr. Hagen's Restricted Stock Agreement with the Company).

In addition, we issued the following inducement stock options: (i) on August 1, 2005, 200,000 inducement stock options to Mr. Klein with an exercise price of \$1.74 per share, and (ii) on October 17, 2005, 550,000 inducement stock options to Mr. Hagen with an exercise price of \$1.83 per share. These options vest with respect to 25% of the option shares upon completion of one year of service measured from the date of grant; the remaining 75% of the option shares vest in a series of 36 equal successive installments upon the completion of each additional month of service thereafter.

These shares of restricted stock and inducement stock options were issued outside of our stock plans in connection with the offers of employment to Messrs. Klein and Hagen. The offer and sale of restricted stock and inducement stock options to Messrs. Klein and Hagen were made pursuant to the exemption set forth in Section 4(2) of the Securities Act of 1933 for transactions not involving a public offering, and regulations promulgated thereunder.

As previously reported by the Company in its Current Report on Form 8-K, filed with the SEC on September 9, 2005, Lawrence P. English stepped down from the positions of Chief Executive Officer and President effective October 17, 2005. In connection therewith, on September 27, 2005, the Company entered into a Transition Agreement with Mr. English, which provided for, among other items, the purchase by the Company of 256,000 restricted shares of common stock from Mr. English on December 31, 2005 to enable Mr. English to satisfy applicable income taxes associated with the lapsing of restrictions on his restricted shares. The purchase price per share of such restricted shares will equal the closing sale price of the Company's common stock on the trading day immediately preceding December 31, 2005.

Item 4. Submission of Matters to a Vote of Security Holders.

The results of the voting at the Company's 2005 Annual Meeting of Stockholders, held on October 26, 2005, were previously reported by the Company in its Current Report on Form 8-K, filed with the SEC on October 31, 2005.

Item 6. Exhibits and Reports on Form 8-K

(a) Exhibits.

The exhibits listed on the accompanying Exhibit Index are filed as part of this Quarterly Report on Form 10-Q.

(b) Reports on Form 8-K.

On July 7, 2005, the Company filed a Form 8-K for its press release of July 5, 2005, announcing Frank J. Pecaitis's resignation as Senior Vice President, Client Development effective July 15, 2005.

On July 8, 2005, the Company filed a Form 8-K for its press release of July 7, 2005, announcing the settlement of the litigation with Mr. James D. Durham.

On July 27, 2005, the Company filed a Form 8-K for its press release of July 27, 2005, announcing the Company's decision to not pursue a possible business combination.

On August 2, 2005, the Company filed a Form 8-K for its press release of August 1, 2005, announcing the release of the Company's 2005 second quarter earnings on August 9, 2005.

On August 15, 2005, the Company filed a Form 8-K for its press release of August 9, 2005, announcing certain management changes and the financial results of Company's second quarter of 2005.

On August 18, 2005, the Company filed a Form 8-K for the transcripts of its investment community conference calls of May 10, 2005 and August 9, 2005.

On August 26, 2005, the Company filed a Form 8-K for Mr. Wright's Separation Agreement and Mr. Milligan's Severance Agreement.

On September 1, 2005, the Company filed a Form 8-K for Mr. Piazza's Employment Agreement and an amendment to the Company's Bylaws.

On September 9, 2005, the Company filed a Form 8-K for its press release of September 7, 2005, announcing a transition in the Company's Chief Executive Officer position.

On September 27, 2005, the Company filed a Form 8-K for its press release of September 20, 2005, announcing the Company's sale of its EDI Division to i-Plexus Solutions, Inc.

On September 29, 2005, the Company filed a Form 8-K for Mr. English's Transition Agreement, Mr. Hagen's Employment Agreement and related agreements, and Mr. Souleles's Separation Agreement.

EXHIBIT INDEX

Certain of the following exhibits have been previously filed with the SEC and are incorporated herein by reference from the document described in parentheses. Certain others are filed herewith.

<u>Exhibit Number</u>	<u>Exhibit Description</u>
2.1	Agreement and Plan of Merger, dated as of September 30, 2004, by and among QuadraMed Corporation, Sawgrass, LLC, Tempus Software, Inc. and each of the shareholders of Tempus Software, Inc. (Exhibit 2.1 to our Current Report on Form 8-K as filed with the SEC on July 15, 2004.)
3.1	Amended and Restated Bylaws of QuadraMed. (Exhibit 3.1 to our Current Report on Form 8-K filed with SEC on October 17, 2005.)
3.2	Third Amended and Restated Certificate of Incorporation of QuadraMed. (Exhibit 3.5 to our Annual Report Amended on Form 10-Q/A, as filed with the SEC on August 24, 1998.)
3.3	Amendment to the Third Amended and Restated Certificate of Incorporation of QuadraMed. (Exhibit 3.3 to our Registration Statement on Form S-1, No. 333-112040 as filed January 21, 2004.)
3.4	Certificate of Designation, Powers, Preferences and Rights of the Series A Cumulative Mandatory Convertible Preferred Shares. (Exhibit 3.1 to our Current Report on Form 8-K as filed with the SEC on September 17, 2004.)
3.5	Certificate of amendment to the Certificate of Designation, Powers, Preferences and Rights of the Series A Cumulative Mandatory Convertible Preferred Shares. (Exhibit 3.1 to our Current Report on Form 8-K filed with the SEC on October 31, 2005.)
4.1	Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4 and 3.5.
4.2	Form of Common Stock certificate. (Exhibit 4.2 to our Registration Statement on Form SB-2, No. 333-5180-LA, as filed with the SEC on September 28, 1996, as amended by Amendment No. 1, Amendment No. 2 and Amendment No. 3 thereto, as filed with the SEC on July 26, 1996, September 9, 1996, and October 2, 1996, respectively.)
4.3	Securities Purchase Agreement, dated as of April 17, 2003, among QuadraMed Corporation and certain investors listed on the signature pages attached thereto. (Exhibit 4.1 to our Current Report on Form 8-K filed with the SEC on April 30, 2003.)
4.4	Warrant Agreement dated as of April 17, 2003, by and between QuadraMed Corporation and The Bank of New York, as warrant agent. (Exhibit 4.3 to our Current Report on Form 8-K filed with the SEC on April 30, 2003.)
4.5	Registration Rights Agreement, dated as of April 17, 2003, among QuadraMed, the investors listed on the signature pages thereto, and Philadelphia Brokerage Corporation. (Exhibit 4.5 to our Current Report on Form 8-K filed with the SEC on April 30, 2003.)
4.6	Form of Warrant to Purchase Common Stock. (Exhibit 4.11 to our Registration Statement on Form SB-2, No. 333-5180-LA, as filed with the SEC on September 28, 1996, as amended by Amendment No. 1, Amendment No. 2 and Amendment No. 3 thereto, as filed with the SEC on July 26, 1996, September 9, 1996, and October 2, 1996, respectively.)
4.7	Registration Rights Agreement dated as of June 30, 2004, by and between QuadraMed and the shareholders identified on the signature pages thereto. (Exhibit 4.1 to our Current Report on Form 8-K as filed with the SEC on July 15, 2004.)
4.8	Form of Preferred Stock certificate for the Series A Cumulative Mandatory Convertible Preferred Shares. (Exhibit 4.17 to our Pre-Effective Amendment No. 3 to our Registration Statement on Form S-1, No. 333- 112040, as filed with the SEC on August 25, 2004.)

<u>Exhibit Number</u>	<u>Exhibit Description</u>
10.1	1996 Stock Incentive Plan of QuadraMed. (Exhibit 10.1 to our Registration Statement on Form SB-2, No. 333-5180-LA, as filed with the SEC on September 28, 1996, as amended by Amendment No. 1, Amendment No. 2 and Amendment No. 3 thereto, as filed with the SEC on July 26, 1996, September 9, 1996, and October 2, 1996, respectively.)
10.2	1996 Employee Stock Purchase Plan of QuadraMed. (Exhibit 10.2 to our Registration Statement on Form SB-2, No. 333-5180-LA, as filed with the SEC on September 28, 1996, as amended by Amendment No. 1, Amendment No. 2 and Amendment No. 3 thereto, as filed with the SEC on July 26, 1996, September 9, 1996, and October 2, 1996, respectively.)
10.3	Summary Plan Description, QuadraMed Corporation 401(k) Plan. (Exhibit 10.3 to our Registration Statement on Form SB-2, No. 333-5180-LA, as filed with the SEC on September 28, 1996, as amended by Amendment No. 1, Amendment No. 2 and Amendment No. 3 thereto, as filed with the SEC on July 26, 1996, September 9, 1996, and October 2, 1996, respectively.)
10.4	Form of Indemnification Agreement between QuadraMed and its directors and executive officers. (Exhibit 10.4 to our Registration Statement on Form SB-2, No. 333-5180-LA, as filed with the SEC on September 28, 1996, as amended by Amendment No. 1, Amendment No. 2 and Amendment No. 3 thereto, as filed with the SEC on July 26, 1996, September 9, 1996, and October 2, 1996, respectively.)
10.5	1999 Supplemental Stock Option Plan for QuadraMed. (Exhibit 10.5 to our annual report on Form 10-K, as filed with the SEC on March 30, 2000, as amended by May 1, 2000.)
10.6	2004 Stock Compensation Plan of QuadraMed. (Exhibit 4.36 to our Registration Statement on Form S-8, No. 333-118581, as filed with the SEC on August 26, 2004.)
10.7	Separation Agreement dated September 12, 2000, between James D. Durham and QuadraMed. (Exhibit 10.64 to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2000, as filed with the SEC on August 14, 2000.)
10.8	Employment Agreement dated September 12, 2000, between Lawrence P. English and QuadraMed. (Exhibit 10.66 to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2000, as filed with the SEC on August 14, 2000.)
10.9	Amendment of Employment Agreement dated September 20, 2001, between Lawrence P. English and QuadraMed. (Exhibit 10.5 to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2001, as filed with the SEC on November 14, 2001.)
10.10	Stock Issuance Agreement dated December 30, 2003, by and between Lawrence P. English and QuadraMed Corporation. (Exhibit 10.24 to our Annual Report on Form 10-K for the year ended December 31, 2003, as filed with the SEC on March 22, 2004.)
10.11	Transition Agreement dated September 27, 2005, between Lawrence P. English and QuadraMed. (Exhibit 99.1 to our Current Report on Form 8-K, as filed with the SEC on September 29, 2005.)
10.12	Employment Agreement dated April 1, 1999, between Michael S. Wilstead and QuadraMed. (Exhibit 10.53 to our Quarterly Report on Form 10-Q for the quarter ended September 30, 1999, as filed with the SEC on August 16, 1999.)
10.13	Amendment of Employment Agreement dated September 20, 2001, between Michael S. Wilstead and QuadraMed. (Exhibit 10.9 to our Quarterly Report on form 10-Q for the quarter ended September 30, 2001, as filed with the SEC on November 14, 2001.)
10.14	Stock Issuance Agreement dated December 30, 2003, by and between Michael S. Wilstead and QuadraMed Corporation. (Exhibit 10.25 to our Annual Report on Form 10-K for the year ended December 31, 2003, as filed with the SEC on March 22, 2004.)

Exhibit Number	Exhibit Description
10.15**	Separation Agreement dated January 5, 2005, between Michael S. Wilstead and QuadraMed.
10.16	Employment Agreement dated August 16, 2000, between Dean Souleles and QuadraMed. (Exhibit 10.67 to our annual report on Form 10-K for the year ended December 31, 2000, as filed with the SEC on April 2, 2001.)
10.17	Amendment of Employment Agreement dated September 19, 2001, between Dean Souleles and QuadraMed. (Exhibit 10.7 to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2001, as filed with the SEC on November 14, 2001.)
10.18	Second Amendment of Employment Agreement dated November 8, 2002, between Dean Souleles and QuadraMed. (Exhibit 10.14 to our Registration Statement on Form S-1, No. 333-112040 as filed January 21, 2004.)
10.19	Separation Agreement dated September 23, 2005, between Dean Souleles and QuadraMed. (Exhibit 99.6 to our Current Report on Form 8-K, as filed with the SEC on September 29, 2005.)
10.20	Employment Agreement dated September 1, 2001, between Frank Pecaitis and QuadraMed. (Exhibit 10.16 to our Registration Statement on Form S-1, No. 333-112040 as filed January 21, 2004.)
10.21	Employment Agreement dated July 9, 2003, between John C. Wright and QuadraMed Corporation. (Exhibit 10.20 to our Annual Report on Form 10-K for the year ended December 31, 2003, as filed with the SEC on March 22, 2004.)
10.22	Inducement Stock Agreement dated July 9, 2003, by and between John C. Wright and QuadraMed Corporation. (Exhibit 10.21 to our Annual Report on Form 10-K for the year ended December 31, 2003, as filed with the SEC on March 22, 2004.)
10.23	Restricted Stock Agreement dated July 9, 2003, by and between John C. Wright and QuadraMed Corporation. (Exhibit 10.22 to our Annual Report on Form 10-K for the year ended December 31, 2003, as filed with the SEC on March 22, 2004.)
10.24	Separation Agreement dated as of August 17, 2005, between John C. Wright and QuadraMed. (Exhibit 99.1 to our Current Report on Form 8-K, as filed with the SEC on August 26, 2005.)
10.25	Employment Agreement dated as of August 10, 2005, between David L. Piazza and QuadraMed Corporation. (Exhibit 99.1 to our Current Report on Form 8-K, as filed with the SEC on September 1, 2005.)
10.26	Employment Agreement dated August 1, 2005, between James R. Klein and QuadraMed Corporation. (Exhibit 99.2 to our Current Report on Form 8-K, as filed with the SEC on August 15, 2005.)
10.27	Inducement Stock Agreement dated as of August 1, 2005, between James R. Klein and QuadraMed Corporation. (Exhibit 99.3 to our Current Report on Form 8-K, as filed with the SEC on August 15, 2005.)
10.28	Restricted Stock Agreement dated as of August 1, 2005, between James R. Klein and QuadraMed Corporation. (Exhibit 99.4 to our Current Report on Form 8-K, as filed with the SEC on August 15, 2005.)
10.29	Severance Agreement dated as of August 22, 2005, between James Milligan and QuadraMed. (Exhibit 99.2 to our Current Report on Form 8-K, as filed with the SEC on August 26, 2005.)
10.30	Employment Agreement dated as of October 17, 2005, between Keith B. Hagen and QuadraMed Corporation. (Exhibit 99.2 to our Current Report on Form 8-K, as filed with the SEC on September 29, 2005.)

<u>Exhibit Number</u>	<u>Exhibit Description</u>
10.31	Inducement Stock Agreement dated as of October 17, 2005, between Keith B. Hagen and QuadraMed Corporation. (Exhibit 99.3 to our Current Report on Form 8-K, as filed with the SEC on September 29, 2005.)
10.32	Restricted Stock Agreement dated as of October 17, 2005, between Keith B. Hagen and QuadraMed Corporation. (Exhibit 99.4 to our Current Report on Form 8-K, as filed with the SEC on September 29, 2005.)
10.33	Proprietary Information and Non-Competition Agreement dated September 26, 2005, between Keith B. Hagen and QuadraMed Corporation. (Exhibit 99.5 to our Current Report on Form 8-K, as filed with the SEC on September 29, 2005.)
10.34	Settlement Agreement dated July 6, 2005, between James D. Durham and QuadraMed Corporation. (Exhibit 99.1 to our Current Report on Form 8-K, as filed with the SEC on July 8, 2005.)
10.35	Negotiable Promissory Note dated July 6, 2005, between James D. Durham and QuadraMed Corporation. (Exhibit 99.2 to our Current Report on Form 8-K, as filed with the SEC on July 8, 2005.)
10.36	Security Agreement dated July 6, 2005, between James D. Durham and QuadraMed Corporation. (Exhibit 99.3 to our Current Report on Form 8-K, as filed with the SEC on July 8, 2005.)
10.37	Lease dated November 19, 1998 for facilities located at 22 Pelican Way, San Rafael, California. (Exhibit 1.7 to our Annual Report on Form 10-K for the year ended December 31, 1999, as filed with the SEC on March 30, 2000.)
10.38	Lease dated November 26, 2001 for facilities located at 1050 Los Vallecitos Boulevard, San Marcos, California. (Exhibit 10.18 to our Registration Statement on Form S-1, No. 333-112040 as filed January 21, 2004.)
10.39	Lease dated September 15, 2001 for facilities located at 12110 Sunset Hills Road, Reston, Virginia. (Exhibit 10.19 to our Registration Statement on Form S-1, No. 333-112040 as filed January 21, 2004.)
10.40	Value Added Remarketing Agreement dated September 26, 1989, by and between InterSystems Corporation and the Compucare Company. (Exhibit 10.28 to our Registration Statement on Form S-1, No. 333-112040, as filed with the SEC on August 25, 2004.)
10.41	Amendment to VAR Agreement between QuadraMed Affinity Corporation and InterSystems Corporation. (Exhibit 10.29 to our Registration Statement on Form S-1, No. 333-112040, as filed with the SEC on August 25, 2004.)
31.1**	Section 302 Certification—CEO
31.2**	Section 302 Certification—CFO
32.1**	Section 906 Certification—CEO
32.2**	Section 906 Certification—CFO

** Filed herewith

SEPARATION AGREEMENT

THIS SEPARATION AGREEMENT (this "AGREEMENT") is entered into as of the fifth day of January, 2005 by and between Michael S. Wilstead ("MR. WILSTEAD"), and QUADRAMED CORPORATION, a Delaware corporation (the "COMPANY").

WHEREAS, Mr. Wilstead was employed by the Company as its President and Chief Operating Officer pursuant to the terms and conditions of that certain employment letter agreement, dated April 1, 1999 between the Company and Mr. Wilstead, and amended by that certain Amendment of Employment Agreement, dated September 20, 2001, between the Company and Mr. Wilstead (collectively, the "EMPLOYMENT AGREEMENT").

WHEREAS, the Board of Directors of the Company has determined that it is in the best interests of the Company and its stockholders to combine the offices of Chief Operating Officer and Chief Executive Officer into one position, and in connection with this determination, Mr. Wilstead shall step down from his positions of President and Chief Operating Officer of the Company.

WHEREAS, such termination of Mr. Wilstead's employment constitutes an "INVOLUNTARY TERMINATION" as defined in the Employment Agreement.

WHEREAS, Mr. Wilstead and the Company wish to enter into an agreement concerning his separation as the Company's President and Chief Operating Officer.

NOW, THEREFORE, in consideration of the mutual promises contained in this Agreement, Mr. Wilstead and the Company agree as follows:

1. **TERMINATION OF EMPLOYMENT RELATIONSHIP.** The parties hereto agree that Mr. Wilstead's employment with the Company as its President and Chief Operating Officer is terminated effective as of January 5, 2005. In exchange for the payments, benefits, and other agreements of the Company set forth in this Agreement, Mr. Wilstead hereby agrees that the Employment Agreement is hereby terminated and canceled effective as of the effective date of this Agreement, with no compensation, benefits, damages, obligations or other payments owing to Mr. Wilstead thereunder (other than as specifically set forth in this Agreement).
2. **CONSIDERATION TO MR. WILSTEAD.** The Company shall make the following payments and provide the following additional benefits and consideration to Mr. Wilstead, subject to Section 6 hereof:
 - a. **SEVERANCE BENEFIT.** As payment in full of its obligations under the Employment Agreement to pay severance benefits upon an Involuntary Termination, the Company will pay to Mr. Wilstead, a lump sum equal to \$305,000 within thirty (30) days of the effective date of this Agreement and will

- continue for a period of 12 months after the date of this Agreement, all life and health plan participation, benefits and other coverages to which Mr. Wilstead and his dependents are currently entitled, pursuant to his Employment Agreement. As of the date of Mr. Wilstead's termination, Mr. Wilstead's long-term disability insurance through the Company will lapse. For a period of 12 months, the Company will pay, or reimburse Mr. Wilstead for, the premiums for a long-term disability policy reasonably selected by Mr. Wilstead with the Company's consent, provided that (i) the Company's payments with respect to such premiums shall not exceed \$1,500 per month and (ii) it is Mr. Wilstead's sole responsibility to qualify for and obtain such long-term disability coverage.
- b. **BONUS COMPENSATION.** Mr. Wilstead shall be entitled to such bonus compensation amounts for fiscal year 2004 as Mr. Wilstead would have received pursuant to the Company's 2004 Incentive Compensation Plan, had Mr. Wilstead been an employee of the Company as of the date for determination of the bonus compensation payment. Such amount shall be paid to Mr. Wilstead at such time as he would have received such bonus payment if he were still an employee of the Company.
 - c. **RESTRICTED SHARES.** With respect to the 344,500 restricted shares of Common Stock of the Company granted to Mr. Wilstead by the Company on February 19, 2002 and December 30, 2003 under the Company's 1996 Stock Incentive Plan as to which, as of the date of termination of the Employment Agreement, applicable restrictions and repurchase rights had not terminated (the "RESTRICTED SHARES"), all restrictions or repurchase rights with respect to all such Restricted Shares shall be deemed to have lapsed, and promptly after execution and delivery of this Agreement and the Exhibits attached hereto the Company shall deliver to Mr. Wilstead certificates representing such shares, such certificates to be without any legends or other restrictions that, subject to any limitation imposed by law on Mr. Wilstead's sale or other transfer of such shares, would preclude Mr. Wilstead's immediate sale or other transfer of such shares.
 - d. **OPTIONS.** The parties hereto agree and acknowledge that the Company's records reflect Mr. Wilstead has currently outstanding options (the "OPTIONS") to purchase a total of 887,500 shares of Common Stock of the Company pursuant to the terms and conditions of the Company's 1996 Stock Incentive Plan, as amended, 569,999 of which are currently vested, and 317,501 of which remain unvested as of the execution of this Agreement. All of Mr. Wilstead's unvested stock options shall automatically accelerate and vest as of the date of this Agreement such that each such option will be immediately exercisable and will remain exercisable for the full term of the applicable option agreement.
 - e. **INDEMNIFICATION; D&O INSURANCE.** Notwithstanding his termination of employment with the Company, Mr. Wilstead (i) shall continue to be entitled to the rights provided by, and subject to the obligations of, Mr. Wilstead's Indemnification Agreement, dated July 15, 1999, with the Company, and (ii) shall

remain covered under the Company's Directors' and Officers' Insurance ("D&O INSURANCE") policy until December 31, 2011, on no less favorable terms than are provided to any other executive officer of the Company, with respect to acts occurring prior to termination of Mr. Wilstead's service as an officer of the Company, and the Company agrees that such D&O Insurance policy shall have policy limits at least as high as the Company's existing policy.

3. TAX EFFECT OF PAYMENTS.

- a. GROSS-UP PAYMENT. In the event that it is determined, pursuant to a binding settlement with the Internal Revenue Service (the "IRS") or pursuant to a judgment of a court of law the time for appeal of which has expired, that any payment or distribution of any type to or for Mr. Wilstead's benefit made by the Company, by any of its affiliates, by any person who acquires ownership or effective control of the Company or ownership of a substantial portion of the Company's assets (within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the "Code") and regulations thereunder) or by any affiliate of such person pursuant to the terms of this Agreement (the "Total Payments") is subject to the excise tax imposed by Section 4999 of the Code or any interest or penalties with respect to such excise tax (such excise tax, together with any such interest or penalties, are collectively referred to herein as the "Excise Tax"), then Mr. Wilstead shall be entitled to receive an additional payment (a "Gross-Up Payment") in an amount such that after payment by Mr. Wilstead of all taxes imposed upon the Gross-Up Payment, including any excise tax imposed by Section 4999 of the Code, Mr. Wilstead retains an amount of the Gross-Up Payment equal to the sum of (i) the Excise Tax imposed on the Total Payments plus (ii) any penalty and interest assessments associated with such Excise Tax.
- b. DETERMINATION OF LIABILITY. In the event that the IRS asserts, or threatens to assert, that any of the Total Payments hereunder is subject to Excise Taxes, Mr. Wilstead shall promptly notify the Company in writing of such assertion or threatened assertion. The Company shall thereupon have the exclusive right and obligation to control, defend, settle, compromise or prosecute in any manner any audit, examination, investigation, hearing or other proceeding with respect to such assertion or threatened assertion by the IRS. Mr. Wilstead agrees to cooperate fully with the Company in such regard (including, without limitation, through the sharing of records and the execution by Mr. Wilstead of any documents or forms, such as powers of attorney, as shall be reasonably requested by the Company).
- c. CALCULATION OF AMOUNT. In the event that the parties hereto are unable to agree as to the amount of the Gross-Up Payment due to Mr. Wilstead pursuant to this Section 3, the parties hereto hereby agree that the amount of the Gross-Up Payment shall be determined by the independent accounting firm then serving as the Company's auditors at the Company's expense.

4. **NON-SOLICITATION AND NON-DISPARAGEMENT.** For one (1) year following the date of this Agreement, Mr. Wilstead will not directly or indirectly (i) solicit any Company employee, independent contractor or consultant to leave the Company's employ or otherwise terminate such person's relationship with the Company for any reason or interfere in any other manner with the employment or other relationships at the time existing between the Company and its current employees, independent contractors or consultants, (ii) solicit any of the Company's customers for products or services substantially similar to those offered by the Company, or (iii) disparage the Company or any of its directors, officers, or employees.
5. **OWNERSHIP RIGHTS.** All materials, ideas, discoveries and inventions pertaining to the Company's business or clients, including (without limitation) all patents and copyrights, patent applications, patent renewals and extensions and the names, addresses and telephone numbers of customers, belong solely to the Company. Mr. Wilstead shall, at all times whether during or after the term of this Agreement, assist the Company, at the Company's sole expense, in obtaining, maintaining, defending and enforcing all legal rights and remedies of the Company, including, without limitation, patents, copyrights and other proprietary rights of the Company. Such assistance will include (without limitation) the execution of documents and assistance and cooperation in legal proceedings.
6. **RELEASES.** As a condition to Mr. Wilstead's entitlement to the compensation, payments and benefits provided for in Section 2 hereof, Mr. Wilstead shall have executed and delivered to the Company a release in the form attached hereto as Exhibit "A" (the "RELEASE"), and such Release shall have become irrevocable. If Mr. Wilstead exercises his right to revoke the Release in accordance with the terms thereof, then this Agreement shall become null and void ab initio. The Company shall execute and deliver to Mr. Wilstead a release in the form attached hereto as Exhibit "B" (the "COMPANY RELEASE").
7. **COOPERATION AND ASSISTANCE.** Mr. Wilstead acknowledges that he may have historical information or knowledge that may be useful to the Company in connection with current or future legal, regulatory or administrative proceedings. Mr. Wilstead will cooperate with the Company in the defense or prosecution of any such claims that relate to events or occurrences that transpired during Mr. Wilstead's employment with the Company. Mr. Wilstead's cooperation in connection with such claims or actions shall include being reasonably available, subject to his other business and personal commitments, to meet with counsel to prepare for discovery or trial and to testify truthfully as a witness when reasonably requested by the Company at reasonable times and with reasonable advance notice to Mr. Wilstead. The Company shall reimburse Mr. Wilstead for (a) if Mr. Wilstead is not solely employed as a consultant, any actual loss of compensation from Mr. Wilstead's then current employer as a result of his cooperation under this Section 7 and any actual loss of compensation (not including travel and other expenses) if Mr. Wilstead is unable to perform any previously scheduled consulting services as a result of his cooperation under this Section 7, (b) if Mr. Wilstead is solely

employed as a consultant and unable to perform any consulting services as a result of his cooperation under this Section 7, an amount equal to the number of hours spent by Mr. Wilstead in cooperating with the Company under this Section 7 multiplied by Mr. Wilstead's then current reasonable hourly consulting rate and (c) any reasonable out-of-pocket expenses, including the reasonable fees of Mr. Wilstead's personal attorney, incurred by Mr. Wilstead in connection with such cooperation.

8. RETURN OF PROPERTY. Except as otherwise provided in this Section 8, Mr. Wilstead expressly agrees that, upon his execution of this Agreement, he will return to the Company all property of the Company including, but not limited to, any and all files, computers, computer equipment and software and diskettes, documents, papers, records, accords, notes, agenda, memoranda, plans, calendars and other books and records of any kind and nature whatsoever containing information concerning the Company or their customers or operations. Mr. Wilstead affirms that he has not retained and will not retain copies of any such property or other materials. Notwithstanding the foregoing, Mr. Wilstead shall not be required to return his computer, rolodexes, personal diaries or correspondence.
9. NON-DISCLOSURE. Under Mr. Wilstead's Employee Confidentiality, Inventions and Non-Competition Agreement with the Company, executed on September 4, 2002, a copy of which is attached to this Agreement as Exhibit "C," and under applicable trade secret law, Mr. Wilstead is obliged to keep in confidence all trade secrets and proprietary and confidential information of the Company, whether patentable or not which he learned or of which he became aware or informed during his employment by the Company (except to the extent disclosure is or may be required by a statute, by a court of law, by any governmental agency having supervisory authority over the business of the Company or by any administrative or legislative body (including a committee thereof) with apparent jurisdiction to order him to divulge, disclose or make accessible such information), and not to directly or indirectly publish, disclose, market or use, or authorize, advise, hire, counsel or otherwise procure any other person or entity, directly or indirectly, to publish, disclose, market or use, any such information. Both under such Employee Confidentiality, Inventions and Non-Competition Agreement and under applicable law, such obligations continue not only while Mr. Wilstead is employed by the Company, but after cessation of that employment. In amplification and not in limitation of the foregoing, Mr. Wilstead acknowledges that during his employment with the Company, he has or may have acquired proprietary and confidential knowledge and information of the Company, including, but not limited to, software, products, "know-how" and other technical data belonging to or relating to the Company, and the identity of customers and suppliers of the Company and the quantities of products ordered by or from and the prices paid by or to those customers and suppliers. In addition, Mr. Wilstead has also acquired similar confidential knowledge and information belonging to customers of the Company and provided to the Company in confidence under written and oral secrecy agreements. Mr. Wilstead agrees to abide by the terms and conditions of the Employee Confidentiality, Inventions and Non-Competition Agreement and of this Section 9 both during his employment by the Company and thereafter. Anything to the contrary notwithstanding, this Section 9 shall not apply to any knowledge or information that has

become generally known in the industry or by the public (other than through a breach of this Agreement or the Employee Confidentiality, Inventions and Non-Competition Agreement by Mr. Wilstead).

10. NO ADMISSION. Nothing in this Agreement shall be deemed to constitute an admission or evidence of any wrongdoing or liability on the part of the Company or Mr. Wilstead and the parties agree that neither this Agreement nor any of the terms or conditions contained herein may be used in any future dispute or proceeding except one to enforce the terms of this Agreement.
11. TAX AND WITHHOLDING. Except as otherwise provided in Section 3, any federal, state and/or local income, personal property, franchise, excise or other taxes owed by Mr. Wilstead as a result of the payments or benefits provided under the terms of this Agreement shall be the sole responsibility and obligation of Mr. Wilstead. Subject to the provisions of Section 3, the parties hereto agree and acknowledge that the Company shall have the right to withhold from any payments made to Mr. Wilstead any and all amounts that are necessary to enable the Company to satisfy any withholding or other tax obligation that arises in connection with such payments or benefits, and the Company shall report any such amounts that it determines are compensation income on Form W-2.
12. NO ORAL MODIFICATION. This Agreement may not be changed orally and no modification, amendment or waiver of any provision contained in this Agreement, or any future representation, promise or condition in connection with the subject matter of this Agreement shall be binding upon any party hereto unless made in writing and signed by such party.
13. RESOLUTION OF DISPUTES. Any disputes under or in connection with this Agreement shall, at the election of either party, be resolved by arbitration, to be held in Reston, Virginia in accordance with the rules and procedures of the American Arbitration Association then in effect. Judgment upon the award rendered by the arbitrator(s) may be entered in any court having jurisdiction. In any action or proceeding brought in connection with this Agreement, the successful party shall be entitled to recover reasonable attorneys' fees in addition to its costs and expenses.
14. INTEGRATION. This Agreement is entered into without reliance upon any statement, representation, promise, inducement or agreement not expressly contained within the terms hereof. This Agreement constitutes the entire agreement between the parties and supersedes all prior oral or written agreements concerning the termination of their employment relationship, regardless of the adequacy of consideration; *provided, however*, that this Agreement does not supercede Mr. Wilstead's Employee Confidentiality, Inventions and Non-Competition Agreement and Indemnification Agreement, which will remain in effect subsequent to the execution of this Agreement to the extent that Mr. Wilstead is no longer an employee of the Company. The Company shall have no obligation to make any payment or do any act other than as specifically set forth herein. The terms of this Agreement are contractual and not mere recitals.

15. SEVERABILITY. In the event that any provision of this Agreement or the application thereof should be held to be void, voidable, unlawful or, for any reason, unenforceable, the remaining portion and application shall remain in full force and effect, and to that end the provisions of this Agreement are declared to be severable.
16. GOVERNING LAW. This Agreement is made and entered into, and shall be subject to, governed by, and interpreted in accordance with the laws of the Commonwealth of Virginia and shall be fully enforceable in the courts of that state, without regard to principles of conflict of laws.
17. SUCCESSORS AND ASSIGNS. This Agreement shall inure to the benefit of and shall be binding upon the parties hereto and their respective heirs, administrators, representatives, executors, successors and permitted assigns, including but not limited to (i) with respect to the Company, any entity with which the Company may merge or consolidate or to which the Company may sell all or substantially all of its assets, and (ii) with respect to Mr. Wilstead, his executors, administrators, heirs and legal representatives.
18. COUNTERPARTS. This Agreement may be executed in counterparts, and each counterpart, when executed, shall have the effect of a signed original.
19. REVOCATION. In accordance with the Older Workers Benefits Protection Act, the Company will hold this offer open for twenty-one (21) days from January 5, 2005, although the Company would hope to conclude this matter as quickly as possible. In addition, Mr. Wilstead may revoke this Agreement at any time within seven (7) days after he signs it. Any revocation must be in writing and delivered to the Company within eight (8) days of signing this Agreement to be effective, and should be transmitted to counsel for the Company, Morris F. DeFeo, Jr., Esq., Miles & Stockbridge, P.C., 1751 Pinnacle Drive, Suite 500, McLean, Virginia 22102, facsimile 703-610-8686. For such revocation to be effective, Mr. DeFeo must receive such written notice not later than the close of business on the seventh day after the day on which Employee executes this Release. Because of Mr. Wilstead's right to revoke this Agreement, it shall not become effective until the eighth (8th) day after it has been signed, and Mr. Wilstead will not be paid any severance pay due to him under this Agreement until after the eighth (8th) day after he signs this Agreement.
20. ACKNOWLEDGMENT OF KNOWING AND VOLUNTARY RELEASE. Mr. Wilstead certifies that he has read the terms of this Agreement. The execution hereof by Mr. Wilstead shall indicate that this Agreement conforms to Mr. Wilstead's understandings and is acceptable to him as a final agreement. It is further understood and agreed that Mr. Wilstead has had the opportunity to consult with counsel of his choice.
21. NOTICES. Any notice required to be given under this Agreement shall be deemed sufficient, if in writing, and sent by certified mail, return receipt requested, via overnight courier, or hand delivered to the Company at 12110 Sunset Hills Road, Reston, Virginia 20190, and to Mr. Wilstead at 332 West Mariposa Drive, Washington, Utah 84780.

IN WITNESS WHEREOF, the parties have executed this Separation Agreement as of the date first above written.

WITNESS:

/s/ Donna Klein

WITNESS:

/s/

QUADRAMED CORPORATION

By: /s/ Lawrence P. English

Name: Lawrence P. English

Title: Chairman and Chief Executive Officer

MICHAEL S. WILSTEAD

/s/ Michael S. Wilstead

RELEASE

KNOW ALL PERSONS BY THESE PRESENTS that the undersigned, Michael S. Winstead (“Employee”), for and in consideration of certain benefits heretofore paid or to be paid or provided to him by QuadraMed Corporation, a Delaware corporation (“QuadraMed”), as such benefits are set forth in a Separation Agreement dated as of January 5, 2005 (the “Separation Agreement”), on behalf of himself and his heirs, executors, administrators, agents, affiliates, successors and assigns, does hereby irrevocably and unconditionally agree to release, waive and forever discharge, except as otherwise provided in this Release, QuadraMed and all of its subsidiaries, affiliates, successors and assigns and their respective directors, officers, employees and agents (collectively, the “Releasees”) from all Claims, as hereinafter defined, and Employee waives, releases and covenants not to sue Releasees or to file any lawsuit or any claim with any Federal, state or local administrative agency asserting or in respect of any of such Claims.

As used in this Release, the term “Claims” means and includes all charges, complaints, claims, liabilities, obligations, promises, agreements, damages, actions, causes of action, rights, costs, losses and expenses (including attorneys’ fees and costs actually incurred) of any nature whatsoever, known or unknown, suspected or unsuspected, which Employee now has, or claims to have, or which Employee at any earlier time had, or claimed to have had, or which Employee at any future time may have, or claim to have, against each or any of the Releasees arising contemporaneously with or prior to the date this Release is executed by Employee or on account of or arising out of any matter, cause or event to occur contemporaneously with or prior to such execution. The Claims that Employee is releasing under this Release include, but are not limited to, rights arising out of alleged violations of any contracts, express or implied, written or oral, and any Claims for wrongful discharge, fraud, misrepresentation, infliction of emotional distress, or any other tort, and any other Claims relating to or arising out of Employee’s employment, compensation and benefits with QuadraMed or the termination thereof, and any Claim for violation of any Federal, state or other governmental statute, regulation or ordinance including, but not limited to, the following, each as amended to date: (1) Title VII of the Civil Rights Act of 1964, 42 U.S.C. §§ 2000e *et seq.*; (2) Section 1981 of the Civil Rights Acts of 1866, 42 U.S.C. § 1981; (3) the Americans with Disabilities Act, 42 U.S.C. § 12101 *et seq.*; (4) the Age Discrimination in Employment Act, 29 U.S.C. §§ 621-634; (5) the Equal Pay Act of 1963, 29 U.S.C. § 206; (6) Executive Order 11246; (7) Executive Order 11141; (8) Section 503 of the Rehabilitation Act of 1973, 29 U.S.C. §§ 701 *et seq.*; (9) the Employee Retirement Income Security Act of 1974, 29 U.S.C. §§ 1001 *et seq.*; (10) the Family and Medical Leave Act, 29 U.S.C. §§ 2601 *et seq.*; (11) the Fair Labor Standards Act, 29 U.S.C. §§ 201 *et seq.*; and (12) any applicable Virginia, California or Delaware law, statute, regulation, ordinance, or constitutional or public policy provisions. Notwithstanding any provision in this Release to the contrary, it is agreed that the Employee does not waive his rights (such rights and the enforcement thereof shall not be “Claims” hereunder) (i) to coverage under any directors and officers insurance policy, (ii) for indemnification pursuant to QuadraMed’s Certificate of Incorporation or Bylaws or any applicable Virginia, California or Delaware law, statute, regulation, ordinance or constitutional or public policy provisions, in each case, as in effect on the date of this Release for acts or omissions occurring or alleged to have occurred during Employee’s employment or other service

to QuadraMed, or (iii) to enforce the Separation Agreement or any rights under any employee or retirement benefit plan, program or policy of QuadraMed, or the Release of this same date under which QuadraMed is releasing claims, if any, that it may assert against Employee.

Employee hereby represents that (i) neither he, nor anyone acting at his discretion or on his behalf, has filed any complaints, charges, claims, demands or lawsuits with respect to any Claim (an "Action") against any Releasee with any governmental agency or any court; (ii) he will not file or pursue any Action at any time hereafter; and (iii) if any such agency or court assumes jurisdiction of any Action, against any Releasee on behalf of Employee, he will request such agency or court to withdraw the matter. If any such Action is filed by the Employee, he further agrees that he will not seek any relief from the Releasees, however that relief might be called, whether reinstatement, back pay, compensatory, punitive or exemplary damages, claims for emotional distress or pain and suffering, or claims for attorneys' fees, reimbursement of expenses or otherwise, on the basis of any such claim. Neither this Release nor the undertaking in this paragraph shall limit Employee from pursuing Claims for the sole purpose of enforcing his rights (i) to coverage under any directors and officers insurance policy, (ii) to indemnification pursuant to QuadraMed's Certificate of Incorporation or Bylaws or any applicable Virginia, California or Delaware law, statute, regulation, ordinance or constitutional or public policy provisions as in effect on the date of this Release for acts or omissions occurring or alleged to have occurred during Employee's employment or other service to QuadraMed, or (iii) to enforce the Separation Agreement or any rights under any employee retirement benefit plan, program, or policy of QuadraMed, or the Release of this same date under which QuadraMed is releasing claims, if any, that it may assert against Employee.

Employee further acknowledges and agrees that all rights that Employee may have under Section 1542 of the California Civil Code or any similar law of any state or the United States are expressly waived. Employee acknowledges that Section 1542 of the California Civil Code provides as follows:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.

As a result of the foregoing, this Release extends to all rights, claims, demands, liabilities, actions, causes of action, damages, losses, costs, expenses and compensation of Employee or his heirs, executors, administrators, agents, affiliates, successors and assigns, whether known or unknown, foreseen or unforeseen, patent or latent, in which Employee may currently or in the future possess, in each case arising contemporaneously with or prior to the date this Release is executed by Employee or on account of or arising out of any matter, cause or event to occur contemporaneously with or prior to such execution. Employee understands and acknowledges the significance of the specific waiver of Section 1542 of the California Civil Code. Employee fully understands and acknowledges that, in the event the facts underlying the foregoing release are found to be other than or different from the facts now understood by

Employee to be true, Employee expressly accepts and assumes the risks of the possible differences in facts and agrees that the release set forth in this Release shall remain in full force and effect, notwithstanding any such difference in facts. Notwithstanding the foregoing, the Releasees agree that Employee does not waive his rights (i) to coverage under any directors and officers insurance policy, (ii) for indemnification pursuant to QuadraMed's Certificate of Incorporation or Bylaws or any applicable Virginia, California or Delaware law, statute, regulation, ordinance or constitutional or public policy provisions as in effect on the date of this Release for acts or omissions occurring or alleged to have occurred during Employee's employment or other service to QuadraMed, or (iii) to enforce the Separation Agreement or any rights under any employee or retirement benefit plan, program or policy of QuadraMed, or the Release of this same date under which QuadraMed is releasing claims, if any, that it may assert against Employee.

This Release is made and entered into, and shall be subject to, governed by and interpreted in accordance with the laws of the Commonwealth of Virginia and shall be fully enforceable in the courts of that state, without regard to principles of conflict of laws.

Employee hereby represents that he has been given a period of twenty-one (21) days to review and consider this Release before signing it. Employee further understands that he may use none or as much of this 21-day period as he wishes prior to signing.

Employee is advised that he has the right to and should consult with an attorney before signing this Release. Employee understands that whether or not to do so is the Employee's decision. Employee has exercised his right to consult with an attorney to the extent if any, that he desired.

Employee may revoke this Release within seven (7) days after he signs it. Revocation can be made by delivering a written notice of revocation to counsel for the Company, Morris F. DeFeo, Jr., Esq., Miles & Stockbridge, P.C., 1751 Pinnacle Drive, Suite 500, McLean, Virginia 22102. For such revocation to be effective, Mr. DeFeo must receive such written notice not later than the close of business on the seventh day after the day on which Employee executes this Release. If Employee revokes this Release, it shall not be effective and the Separation Agreement shall be null and void ab initio.

Employee acknowledges that he has read this release, understands it and is voluntarily executing it and that no representations, promises or inducements have been made to Employee except as set forth in this release voluntarily, and that he intends to be legally bound by its terms, with full understanding of its consequences.

Please read this Release carefully. It covers all known and unknown claims arising contemporaneously with or prior to the date this Release is executed or on account of or arising out of any matter, cause or event to occur contemporaneously with or prior to such execution including claims under the Federal Age Discrimination in Employment Act.

[Signatures on following page.]

Executed at Scottsdale, AZ, on January 5, 2005.

WITNESS:

/s/

MICHAEL S. WILSTEAD

/s/ Michael S. Wilstead

RELEASE

KNOW ALL PERSONS BY THESE PRESENTS that QuadraMed Corporation, a Delaware corporation, (“QuadraMed”), for itself and all of its subsidiaries, affiliates, successors and assigns and their respective directors, officers, employees and agents, for and in consideration of the execution and delivery by Michael S. Winstead (“Releasee”) of a Separation Agreement dated as of January 5, 2005 (the “Separation Agreement”), does hereby irrevocably and unconditionally agree to release, waive and forever discharge, except as otherwise provided in this Release, Releasee from all Claims, as hereinafter defined, and QuadraMed waives, releases and covenants not to sue Releasee or to file any lawsuit or any claim with any Federal, state or local administrative agency asserting or in respect of any of such Claims.

As used in this Release, the term “Claims” means and includes all charges, complaints, claims, liabilities, obligations, promises, agreements, damages, actions, causes of action, rights; costs, losses and expenses (including attorneys’ fees and costs actually incurred) of any nature whatsoever, known or unknown, suspected or unsuspected, which QuadraMed or any of its subsidiaries, affiliates, successors and assigns now has, or claims to have, or which QuadraMed or any of its subsidiaries, affiliates, successors and assigns at any earlier time had, or claimed to have had, or which QuadraMed or any of its subsidiaries, affiliates, successors and assigns at any future time may have, or claim to have, against the Releasee arising contemporaneously with or prior to the date this Release is executed by QuadraMed or on account of or arising out of any matter, cause or event to occur contemporaneously with or prior to such execution.

QuadraMed hereby represents that (i) neither it nor anyone acting at its discretion or on its behalf has filed any complaints, charges, claims, demands or lawsuits with respect to any Claim (an “Action”) against the Releasee with any governmental agency or any court; (ii) it will not file or pursue any Action at any time hereafter; and (iii) if any such agency or court assumes jurisdiction of any Action against the Releasee on behalf of QuadraMed, QuadraMed will request such agency or court to withdraw the matter. Neither this Release nor the undertaking in this paragraph shall limit QuadraMed from pursuing Claims for the sole purpose of enforcing its rights under the Separation Agreement and the Release of this same date under which the Releasee releases Claims, if any, that he might assert against QuadraMed.

QuadraMed further acknowledges and agrees that all rights that QuadraMed may have under Section 1542 of the California Civil Code or any similar law of any state or the United States are expressly waived. QuadraMed acknowledges that Section 1542 of the California Civil Code provides as follows:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.

As a result of the foregoing, this Release extends to all rights, claims, demands, abilities, actions, causes of action, damages, losses, costs, expenses and compensation of QuadraMed or any of its subsidiaries, affiliates, successors and assigns, whether known or unknown, foreseen or unforeseen, patent or latent, in which QuadraMed or any of its subsidiaries, affiliates, successors and assigns may currently or in the future possess in each case arising contemporaneously with or prior to the date this Release is executed by Employee or on account of or arising out of any matter, cause or event to occur contemporaneously with or prior to such execution. QuadraMed understands and acknowledges the significance of the specific waiver of Section 1542 of the California Civil Code. QuadraMed fully understands and acknowledges that, in the event the facts underlying the foregoing release are found to be other than or different from the facts now understood by QuadraMed to be true, QuadraMed expressly accepts and assumes the risks of the possible differences in facts and agrees that the release set forth in this Release shall remain in full force and effect, notwithstanding any such difference in facts.

This Release is made and entered into, and shall be subject to, governed by and interpreted in accordance with the laws of the Commonwealth of Virginia and shall be fully enforceable in the courts of that state, without regard to principles of conflict of laws.

Executed at Reston, VA on January 11, 2005.

WITNESS:

/s/ Donna Klein

QUADRAMED CORPORATION

By: /s/ Lawrence P. English

Name: Lawrence P. English

Title: Chairman and Chief Executive Officer

EMPLOYEE CONFIDENTIALITY, INVENTIONS AND NON-COMPETITION AGREEMENT

QUADRAMED CORPORATION
SARBANES-OXLEY ACT SECTION 302 CERTIFICATION

CEO Certification

I, Keith B. Hagen, certify that:

1. I have reviewed this quarterly report on Form 10-Q of QuadraMed Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal controls over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 9, 2005

/s/ KEITH B. HAGEN

Keith B. Hagen
Chief Executive Officer

QUADRAMED CORPORATION
SARBANES-OXLEY ACT SECTION 302 CERTIFICATION

CFO Certification

I, David L. Piazza, certify that:

1. I have reviewed this quarterly report on Form 10-Q of QuadraMed Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal controls over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 9, 2005

/s/ DAVID L. PIAZZA

David L. Piazza
Chief Financial Officer

QUADRAMED CORPORATION
SARBANES-OXLEY ACT SECTION 906 CERTIFICATION

In connection with this Quarterly Report on Form 10-Q of QuadraMed Corporation for the period ended September 30, 2005, I, Keith B. Hagen, Chief Executive Officer of QuadraMed Corporation, hereby certify pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1. This Form 10-Q for the period ended September 30, 2005 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in this Form 10-Q for the period ended September 30, 2005 fairly presents, in all material respects, the financial condition and results of operations of QuadraMed Corporation.

Date: November 9, 2005

/s/ KEITH B. HAGEN

Keith B. Hagen
Chief Executive Officer

**QUADRAMED CORPORATION
SARBANES-OXLEY ACT SECTION 906 CERTIFICATION**

In connection with this Quarterly Report on Form 10-Q of QuadraMed Corporation for the period ended September 30, 2005, I, David L. Piazza, Chief Financial Officer of QuadraMed Corporation, hereby certify pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1. This Form 10-Q for the period ended September 30, 2005 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in this Form 10-Q for the period ended September 30, 2005 fairly presents, in all material respects, the financial condition and results of operations of QuadraMed Corporation.

Date: November 9, 2005

/s/ DAVID L. PIAZZA

David L. Piazza
Chief Financial Officer